Domain > www.emrelis.com

More information on this domain is in AlienVault OTX

DNS Resolutions

Date	IP Address
2025-03-26	18.238.4.125 (ClassC)
2026-02-24	3.169.173.7 (ClassC)

HTTP/1.1 200 OKContent-Type: text/html;charsetutf-8Content-Length: 145806Connection: keep-aliveDate: Tue, 24 Feb 2026 14:07:29 GMTCache-Control: max-age0, s-maxage86400Set-Cookie: AWSALBD5iTrfWKiKqYv6ajCgR6Aysrnfh73fpYrvJ+vYhg4ipRTnKVRqIqO9OgACuaGxx/SWCRK9LQqMNM308bJk8BgT1Wa4fUL8UQIIbfr64Ksix4i3c8ckqDfMN2AQUK; ExpiresTue, 03 Mar 2026 14:07:29 GMT; Path/Set-Cookie: AWSALBCORSD5iTrfWKiKqYv6ajCgR6Aysrnfh73fpYrvJ+vYhg4ipRTnKVRqIqO9OgACuaGxx/SWCRK9LQqMNM308bJk8BgT1Wa4fUL8UQIIbfr64Ksix4i3c8ckqDfMN2AQUK; ExpiresTue, 03 Mar 2026 14:07:29 GMT; Path/; SameSiteNone; SecureServer: X-Frame-Options: SAMEORIGINStrict-Transport-Security: max-age31536000; includeSubDomainsX-Content-Type-Options: nosniffLast-Modified: Thu, 19 Feb 2026 19:26:28 GMTETag: 2398e-64b3248009749Accept-Ranges: bytesX-Dispatcher: dispatcher1useast1-b80X-Vhost: publishVary: Accept-EncodingX-Cache: Miss from cloudfrontVia: 1.1 a454a679efa1e16833b77cb6af61e11c.cloudfront.net (CloudFront)X-Amz-Cf-Pop: HIO52-P4X-Amz-Cf-Id: c-5NXcTcxGPPr7Ge-adiFOXSV2lTzY5PzxXV-Zu2iJoazqpbWC0Z2A

!DOCTYPE HTML>html langen-US>                        head>meta http-equivcontent-type contenttext/html; charsetUTF-8/>meta charsetutf-8/>meta nameviewport contentwidthdevice-width, initial-scale1/>					script deferdefer typetext/javascript srchttps://rum.hlx.page/.rum/@adobe/helix-rum-js@%5E2/dist/rum-standalone.js data-routingenvprod,tierpublish,amsAbbvie Commercial>/script>link relshortcut icon sizes196x196 href/content/dam/emrelis/images/homepage/emrelis-favicon-180x180_r0_allviews.svg/_jcr_content/renditions/cq5dam.thumbnail.196.196.png/>					link relapple-touch-icon sizes180x180 href/content/dam/emrelis/images/homepage/emrelis-favicon-180x180_r0_allviews.svg/_jcr_content/renditions/cq5dam.thumbnail.180.180.png/>					link relapple-touch-icon sizes120x120 href/content/dam/emrelis/images/homepage/emrelis-favicon-180x180_r0_allviews.svg/_jcr_content/renditions/cq5dam.thumbnail.120.120.png/>					link relapple-touch-icon sizes167x167 href/content/dam/emrelis/images/homepage/emrelis-favicon-180x180_r0_allviews.svg/_jcr_content/renditions/cq5dam.thumbnail.167.167.png/>					link relapple-touch-icon sizes57x57 href/content/dam/emrelis/images/homepage/emrelis-favicon-180x180_r0_allviews.svg/_jcr_content/renditions/cq5dam.thumbnail.57.57.png/>					link relapple-touch-icon sizes152x152 href/content/dam/emrelis/images/homepage/emrelis-favicon-180x180_r0_allviews.svg/_jcr_content/renditions/cq5dam.thumbnail.152.152.png/>					link relicon sizes32x32 href/content/dam/emrelis/images/homepage/emrelis-favicon-180x180_r0_allviews.svg/_jcr_content/renditions/cq5dam.thumbnail.32.32.png/>	!-- Custom Meta tags added as authored -->								meta contentEMRELIS™ (telisotuzumab-vedotin) – Official Patient Site propertyog:title/>										meta contentEMRELIS™ (telisotuzumab-vedotin) is a c-Met ADC for patients with advanced NSCLC. Learn more on the patient site propertyog:description/>										meta contenthttps://www.emrelis.com/ propertyog:url/>										meta contentwebsite propertyog:type/>										meta contentEMRELIS propertyog:site_name/>				!-- **** MRP Meta Tags **** -->!-- ****Removed redirect.html from body and added in head to fix server side redirection **** -->	    link reldns-prefetch hrefhttps://use.typekit.net/>    link reldns-prefetch hrefhttps://p.typekit.net/>    link reldns-prefetch hrefhttps://dpm.demdex.net/>    link reldns-prefetch hrefhttps://fast.abbviecommercial.demdex.net/>    link reldns-prefetch hrefhttps://abbviecommercial.demdex.net/>    link reldns-prefetch hrefhttps://abbviecommercial.tt.omtrdc.net/>    link reldns-prefetch hrefhttps://smetrics.abbvie.com/>    link reldns-prefetch hrefhttps://assets.adobedtm.com/>                meta namekeywords contentNSCLC/>                    meta namedescription contentEMRELIS™ (telisotuzumab-vedotin) is a c-Met ADC for patients with advanced NSCLC. Learn more on the patient site/>                        meta namelanguage contenten/>                    meta namecountry contentUS/>            meta namepagename contentEMRELIS™ (telisotuzumab-vedotin) – Official Patient Site/>    meta nametemplatename contentfull-width-content-page/>    meta namepageurl content//>            meta namefranchise contentSolid Tumors/>                    meta namecontent-journey contentbrand benefit/>                    meta namepatient-journey contentother/>                        meta nameforcedmodaloverlay contentno/>                meta nameindication-id contentnsclc/>                    meta namesitename contentEmrelis/>                    meta nameglobalisi contentUS-TEL-250027/>                    meta nameepassnumber contentUS-TEL-240039 v1/>        						    script src/etc/clientlibs/common-elements/clientlibs/plugins/clientlib.min.d2454d9f632f1f286ab2bca6de3f7e29.js>/script>				                link relstylesheet href/etc/clientlibs/common-elements/clientlibs/v1/css-clientlib-all.min.5febd4d926b716ee3388cab0123d5974.css typetext/css>                    !-- Site Level CSS -->            link relpreload href/content/dam/emrelis/css/emrelis-global.css asstyle/>        link relstylesheet href/content/dam/emrelis/css/emrelis-global.css typetext/css/>        !-- Page Level CSS -->                                                                            script>        window.AbbViePageInfo  {            loginPage : ,            forcedLogin : ,            editState: false,            pagepath: /content/emrelis/en-us,            adminConfigPath: /content/admin/emrelis/en-us,            apiEndPoints: {getPatientFullfilment: /api/BrandAPIGateway/api/V2/PatientFulfillment/GetPatientFulfillment,saveAssessment: /api/BrandAPIGateway/api/Assessment/Save,physicianLookUp: /api/BrandAPIGateway/api/Physician/LookUp,getAssessment: /api/BrandAPIGateway/api/Assessment/Get,getAggregated: /api/BrandAPIGateway/api/Assessment/GetAggregated,refreshToken: /bin/abbvieforms/refreshlogin,getSearchSuggestions: /suggest,getSearchResults: /search,apigeePhysicianLookUp: /bin/abbvie/apiproxy,apigeeProviderLookUp: /bin/abbvie/providerlookupapiproxy,infusionSiteLocator: /bin/abbvie/providerlookupapiproxy},            share: {facebook:{},twitter:{},linkedin:{},tumblr:{},pinterest:{},email:{},copy:{},instagram:{}},            brandConfig : fm-brandname-emrelis,            headers:,            targetTimeout: 1000,            timeOut :,            originNames:,            indicationName : nsclc,            indicationReset : false,            epassNumber : US-TEL-240039 v1,            indicationAware : true,            indicationEndPoints :{                header: /{{indication}}/jcr:content/headerIpar.html,                footer: /{{indication}}/jcr:content/footerIpar.html,                safetyBar: /{{indication}}/jcr:content/safetybar.html,                inlineUse: /content/global/en-us/emrelis/consumer/{{indication}}/use/jcr:content/contentpar.html,                inlineISI: /content/global/en-us/emrelis/consumer/{{indication}}/isi/jcr:content/contentpar.html            },            campaignConfig : {sids:{},emids:{},qids:{},videooptionids:{},eids:{},optionids:{}},            runModes: prod, s7connect, crx3, nosamplecontent, publish, crx3tar,            friendlyNames: ,            coveoSearchHub:,            coveoSearchUrl:https://platform.cloud.coveo.com/rest/search,            coveoOrganizationId:abbvieincproductionyd9g1cpe,            coveoHostedSearchPageAPIKey:xx63ab8217-2b82-4c4a-967f-d6894f422ff3,            coveoQuerySuggestionsEnabled:false,            admpInvisibleEntRecaptchaSitekey : 6Ld-4xkiAAAAAIqU4DUDupoGer6ss43KQeOGEtk0,            maxComponentCount: 100,            headerInheritance: ,            footerInheritance: ,            safetybarInheritance: ,            globalFooterLinks: { 	"findLinkText": "PRIVACY POLICY", 	"newLinkText": "Consumer Health Data Privacy Notice", 	"newLinkUrl": "https://abbv.ie/PrivacyConsumerHealth", 	"language": "en" }, { 	"findLinkText": "PRIVACY Notice", 	"newLinkText": "Consumer Health Data Privacy Notice", 	"newLinkUrl": "https://abbv.ie/PrivacyConsumerHealth", 	"language": "en" }, { 	"findLinkText": "Aviso De privacidad", 	"newLinkText": "Aviso de Privacidad de los Datos de Salud de los Consumidores", 	"newLinkUrl": "https://abbv.ie/PrivacidadConsumidores", 	"language": "es" }, { 	"findLinkText": "Aviso De privacidad", 	"newLinkText": "Aviso de Privacidad de los Datos de Salud de los Consumidores", 	"newLinkUrl": "https://abbv.ie/PrivacidadConsumidores", 	"language": "es-pr" },            pageAudienceType: Patient        };        /script>                script>//Dont use let/const for global definitions here b/c this code is also in pre-load-utils.jsvar cookieObj  (function() {	//NOTE: Unlikely that we have cookie names/values with spaces or special characters, but encode/decode just in case	//NOTE: Chrome now sets a max cookie age of 400, even if a larger value is passed	return {		init: function() {			// no longer needed - left for back-compat (forms code)		},		/**		 * Retrieve a cookie value		 * @param {String} name cookie name		 * @returns {String} cookie value, or undefined if not found		 */		getCookie: function(name) {			if (!name) {				return undefined;			}			name  encodeURIComponent(name);			let value  document.cookie.split(; ).find((c) > c.startsWith(name + ));			return value ? decodeURIComponent(value.split()1) : undefined; 		},		/**		 * Set a cookie value on root path		 * @param {String} name cookie name 		 * @param {String} value cookie value		 * @param {Number} days0 number of days for cookie to persist. 0 (falsy value) sets session cookie. Negative value deletes cookie.		 * @param {Boolean} notSecurefalse true to set unsecure cookie (not advised)		 */		createCookie: function(name, value, days, notSecure) {			let expires;			if (days) {				let date  new Date();				date.setTime(date.getTime() + (days * 24 * 60 * 60 * 1000));				expires  ; expires + date.toGMTString();			} else {				expires  ;  //session cookie			}			document.cookie  encodeURIComponent(name) +  + encodeURIComponent(value) + expires + ; path/; + (notSecuretrue ?  : secure);			//Should evaluate any cookies explicity set to unsecure			if (notSecure  true) {				console.log(cookieObj: wrote unsecure cookie - name + name);			}		},		/**		 * Delete a cookie		 * @param {String} name cookie name		 */		deleteCookie: function(name) {			this.createCookie(name, , -1);		}	};})();var urlObj  (function() {	var queryVars  {};	var queryVarsU  {};	return {		init : function(){			urlObj.analzeQuery();		},		analzeQuery : function(){			var qString  window.location.search.split(?)1;			if(qString ! undefined){				var temp  qString.split(&);				for(let i  0; i  temp.length; i++){					let tempSplit  tempi.split();					queryVarstempSplit0  tempSplit1;					queryVarsUtempSplit0.toUpperCase()  tempSplit1;				}			}		},		getParam : function(key, caseSensative){			caseSensative  caseSensative  undefined ? true : caseSensative;			let val;			if(caseSensative){ val  decodeURIComponent(queryVarsencodeURIComponent(key));}			else { val  decodeURIComponent(queryVarsUencodeURIComponent(key.toUpperCase()));}			return val;		},		getParamsObj : function (){			return queryVars;		},		getParamsObjU : function (){			return queryVarsU;		},		printObj : function(){			console.log(queryVars);			console.log(queryVarsU);		}	};})();var campaignTracking  (function() {	var idTables;	var gpf_payload  {};	var sa_payload  {		CampaignMasterId:,		CompleteDate:null,		ConsumerId:,		IndividualId:,		AssessmentQuestion: {			QuestionId:,			QuestionOptions:{				OptionId:,				ResponseText:			}		},		OtherInformation:{}	};	var questionLookupReq  false;	var saveReady  false;	return {		init : function(){			idTables  AbbViePageInfo.campaignConfig;      		AbbViePageInfo.campaignTracking  {};			if(campaignTracking.getIndividualID()){				// console.log(-- Individual ID Found --);				AbbViePageInfo.campaignTracking.individualID  sa_payload.IndividualId;				if(campaignTracking.getCampaignMasterID()){					// console.log(-- Campaign Master ID Found --);					AbbViePageInfo.campaignTracking.campaignMasterId  sa_payload.CampaignMasterId;					if(campaignTracking.getOptionID()){						// console.log(-- Option ID Found --);						if(campaignTracking.getQuestionID()){							// console.log(-- Question ID Found --);							saveReady  true;						}						campaignTracking.getAdditionalInfo();					}				}			}			if(saveReady){				campaignTracking.saveAssessment();			}		},		getIndividualID : function (){			let haveInfo  false;			if(urlObj.getParam(s_fid,false) ! undefined){				gpf_payload.Source  Intouch;				gpf_payload.FulfillmentID  urlObj.getParam(s_fid,false);				haveInfo  true;				// return true;			} else if (urlObj.getParam(h_fid,false) ! undefined){				gpf_payload.Source  Epsilon;				gpf_payload.FulfillmentID  urlObj.getParam(h_fid,false);				haveInfo  true;				// return true;			} else if (urlObj.getParam(fid) ! undefined){				gpf_payload.Source  Epsilon;				gpf_payload.FulfillmentID  urlObj.getParam(fid,false);				haveInfo  true;				// return true;			} else {				console.log(missing fid variant);				// return false;			}			if(haveInfo){				//Ajax call to get individual ID				let url  AbbViePageInfo.apiEndPoints.getPatientFullfilment;				let successState  false;				ajaxCall(url, POST, JSON.stringify(gpf_payload), gpfSuccess, gpfFail);				//Success				function gpfSuccess(data){					//Set to sa_payload					if(data.ContentResult && data.ContentResult.IndividualId){						var id  data.ContentResult.IndividualId;						sa_payload.IndividualId  id;						sessionStorage.setItem(IndividualId,id);						//Write cookie						successState  true;					}				}				//Fail				function gpfFail(jqXHR, textStatus, errorThrown){					//return false					console.log(Get Patient Fullfillment Fail);					successState  false;				}				return successState;			} else {				return false;			}		},		getCampaignMasterID : function(){			if(urlObj.getParam(mcid,false) ! undefined){				sa_payload.CampaignMasterId  urlObj.getParam(mcid,false);				return true;			} else if (urlObj.getParam(em_id) ! undefined){				sa_payload.CampaignMasterId  idTables.emidsurlObj.getParam(em_id);				questionLookupReq  true;				return true;			} else if (urlObj.getParam(sid) ! undefined){				sa_payload.CampaignMasterId  idTables.sidsurlObj.getParam(sid);				questionLookupReq  true;				return true;			} else if (urlObj.getParam(qID) ! undefined){				sa_payload.CampaignMasterId  idTables.qidsurlObj.getParam(qID);				questionLookupReq  true;				return true;			} else if (urlObj.getParam(eid) ! undefined){				sa_payload.CampaignMasterId  idTables.eidsurlObj.getParam(eid);				questionLookupReq  true;				return true;			} else {				console.log(missing master campaign id in query or corresponding id);				return false;			}		},		getQuestionID : function(){			if(questionLookupReq){				// console.log(Question Id lookup Required);				let successState  false;				let cmi_query  ?CampaignMasterId+sa_payload.CampaignMasterId;				let url  AbbViePageInfo.apiEndPoints.getAssessment+cmi_query;				ajaxCall(url, GET, , getAssessmentSuccess, getAssessmentFail);				function getAssessmentSuccess(data){					// console.log(getAssessmentSuccess);					if(data.IsStatusSuccessful){						var matchOption  sa_payload.AssessmentQuestion0.QuestionOptions0.OptionId;						var questionList  data.ContentResult.AssessmentQuestion;						var matchedQuestionID  campaignTracking.reverseLookup(questionList, matchOption);						if(matchedQuestionID ! undefined){							sa_payload.AssessmentQuestion0.QuestionId  matchedQuestionID;							successState  true;							// console.log(reverse lookup found question id);						} else { console.log(no option id matching in campaign);}					} else {						console.warn(getAssessment status successful  false);					}				}				function getAssessmentFail(jqXHR, textStatus, errorThrown){console.log(getAssessmentFail);}				return successState;			} else {				if(urlObj.getParam(qid) ! undefined){					sa_payload.AssessmentQuestion0.QuestionId  urlObj.getParam(qid);					return true;				}				else {					console.log(missing question id in query or corresponding id);					return false;				}			}		},		getOptionID : function(){			if(urlObj.getParam(oid,false) ! undefined){				sa_payload.AssessmentQuestion0.QuestionOptions0.OptionId  urlObj.getParam(oid,false);				return true;			} else if (urlObj.getParam(eid) ! undefined){				if(urlObj.getParam(qid) ! undefined){					let lookup  urlObj.getParam(eid) + urlObj.getParam(qid);					if(idTables.optionidslookup ! undefined){						sa_payload.AssessmentQuestion0.QuestionOptions0.OptionId  idTables.optionidslookup;						return true;					} else {						console.warn(eid + qid no option id to match);						return false;					}				}				console.log(missing qid for looking up eid + qid);			} else if (urlObj.getParam(q1,false) ! undefined){				sa_payload.AssessmentQuestion0.QuestionOptions0.OptionId  urlObj.getParam(q1,false);				return true;			} else {				console.log(missing option id in query or corresponding id);				return false;			}		},		getAdditionalInfo : function(){			if (urlObj.getParam(cid,false) ! undefined){				sa_payload.OtherInformation.cid  urlObj.getParam(cid,false);				return true;			} else if (urlObj.getParam(s_mcid,false) ! undefined){				sa_payload.OtherInformation.cid  urlObj.getParam(s_mcid,false);				return true;			}			if(urlObj.getParam(ep_ind,false) ! undefined){				sa_payload.OtherInformation.cid  urlObj.getParam(cid,false);				return true;			}		},		reverseLookup : function(data, optionID){			for(let i  0; i  data.length; i++){				let optionList  datai.QuestionOption;				let tempQuestion  datai.QuestionId;				for (let k  0; k  optionList.length; k++){					if(optionListk.OptionId.toUpperCase()  optionID.toUpperCase()){						return tempQuestion;					}				}			}		},		saveAssessment : function(){			let url  AbbViePageInfo.apiEndPoints.saveAssessment;			ajaxCall(url, POST, JSON.stringify(sa_payload), saveAssessmentSuccess, saveAssessmentFail);			function saveAssessmentSuccess(){				console.log(Save Asessement Success);			}			function saveAssessmentFail(jqXHR, textStatus, errorThrown){				console.error(Save Assessment Fail);			}		},		printPayloads : function(){			console.log(gpf_payload);			console.log(sa_payload);		}	};})();function setHeaders(url, xhr){	xhr.setRequestHeader(content-type,application/json);	// If call is a save assessment call	if(AbbViePageInfo.apiEndPoints.saveAssessment  url){		let acMcIdCookie  cookieObj.getCookie(ac_mcid);		if(acMcIdCookie ! undefined){			xhr.setRequestHeader(MId,acMcIdCookie);		}	}}function ajaxCall(url, type, payload, successCallback, failedCallback, async, dataType){	var xhr  new XMLHttpRequest();	xhr.open(type, url, async  true);	setHeaders(url, xhr);	xhr.addEventListener(error, failedCallback);	xhr.onreadystatechange  function(){		if(xhr.readyState  4){			var data;			// console.log(XHR: Request Done);			if(xhr.status ! 200){				if(Array.isArray(failedCallback)){					for(var f  0; f  failedCallback.length; f++){						failedCallbackf(data, xhr.statusText, xhr);					}				} else {					failedCallback(data, xhr.statusText, xhr);				}			} else {				//HACK: for some reason an API is returning a 200/OK, but content-type is null				if (xhr.getResponseHeader(content-type) && xhr.getResponseHeader(content-type).includes(application/json)) {					data  JSON.parse(xhr.responseText);				} else {					data  xhr.responseText;				}				if(Array.isArray(successCallback)){					for(var s  0; s  successCallback.length; s++){						successCallbacks(data, xhr.statusText, xhr);					}				} else {					successCallback(data, xhr.statusText, xhr);				}			}		}	};	if(payload ! ){		xhr.send(payload);	} else {		xhr.send();	}}function addWindowLoad(func) {	var oldonload  window.onload;	 if (typeof window.onload ! function) {		  window.onload  func;	}	  // window load event is not getting triggered for the IOS having video inside XF pages */	else if (browserAgent.checkIfBrowser(safari) ||  browserAgent.checkIfBrowser(mSafari)) {		  if($(video-js).length) {			  window.addEventListener(load,  func());		  }	  }	else {	  window.onload  function() {		if (oldonload) {		  oldonload();		}		func();	  };	}  }var postLoadActions  (function() {	var pageLoadQueue  ;	var waitFlags  0;	var pageLoadImportance  		isi,		modal-once,		modal-always,		modal-indication,		modal-hash,		ftvid,		pageScroll	;	return {		addPageLoadStack: function(func,type) {			let priority  pageLoadImportance.indexOf(type);			let newFunc  {				priority : priority,				func : func			};			if (!pageLoadQueue.length) {				pageLoadQueue.push(newFunc);			} else {				if (!postLoadActions.checkExistence(type)) {					let insertIndex  pageLoadQueue.length;					for (let i  0; i  pageLoadQueue.length; i++) {						if(priority > pageLoadQueuei.priority){							insertIndex  i;							break;						}					}					pageLoadQueue.splice(insertIndex, 0, newFunc);				}			}		},		addWaitFlag: function(){waitFlags++; },		removeWaitFlag: function(){waitFlags--;},		isWaiting: function(){return waitFlags ! 0;},		isReady: function(){return waitFlags  0;},		pop: function(){			if (pageLoadQueue.length) {				let popped  pageLoadQueue.pop();				popped.func();			} else {				return;			}		},		checkExistence: function(type){			let priority  pageLoadImportance.indexOf(type);			let isAvailable  false;			if (pageLoadQueue.length) {				for (let i  0; i  pageLoadQueue.length; i++) {					if(priority  pageLoadQueuei.priority){						isAvailable  true;						break;					}				}			}			return isAvailable;		},		printObj: function(){			console.log(pageLoadQueue);		}	};})();//Initialize urlObj, campaignTrackingurlObj.init();campaignTracking.init();if (urlObj.getParam(cid) ! undefined) {	cookieObj.createCookie(admp_cid, urlObj.getParam(cid));}if (urlObj.getParam(segid) ! undefined) {	cookieObj.createCookie(admp_segid, urlObj.getParam(segid));}//Create indicationName cookie or delete if this page is indication-resetif (AbbViePageInfo.indicationName && AbbViePageInfo.indicationName ! generic-indication) {	cookieObj.createCookie(indicationName, AbbViePageInfo.indicationName);} else if (AbbViePageInfo.indicationReset  true) {	cookieObj.deleteCookie(indicationName);}//Indication on url overrides page propertyif (urlObj.getParam(indicationName) ! undefined) {	cookieObj.createCookie(indicationName, urlObj.getParam(indicationName));}let forceScroll  function () {	let sectionId  urlObj.getParam(section, false);	if (sectionId ! undefined) {		scrollToObject($(html,body), $(# + sectionId), 0, slow);	}};postLoadActions.addPageLoadStack(forceScroll, pageScroll);	// Check and set load states for reference with XFsvar abbvPageLoaded  false;var loadUpdateFunction  function() {	abbvPageLoaded  true;};addWindowLoad(loadUpdateFunction);/script>            link relcanonical hrefhttps://www.emrelis.com//>!-- **** ABBVIE Configs LIBRARY **** -->!-- sly data-sly-includeconfigs.html /> -->!-- **** ABBVIE ANALYTICS LIBRARY **** -->	    script>    var digitalData  {            page: {                pageInfo: {                    domain: emrelis,                    subDomain: ,                    url: https://www.emrelis.com/content/emrelis/en-us,                    path: /content/emrelis/en-us,                    pageName: en-us,                    title: EMRELIS  (telisotuzumab vedotin) – Official Patient Site,                    prefix: emrelis                },                category: {                    primaryCategory: homepage,                    subCategory1: ,                    subCategory2:                 },                attributes: {                    country: us,                    language: en,                    template: full width content page,                    promoMatsNumber: US-TEL-240039 v1,                    globalISI: US-TEL-250027,                    type: homepage                },                journey: {                    content: brand benefit,                    patient: other,                    messageBucket:                 },                product: {                    name: telisotuzumab vedotin,                    franchise: Solid Tumors,                    indication: Non Small Cell Lung Cancer (NSCLC),                    division: Oncology,                    brand: Emrelis                },                site: {                    type: branded,                    experience: responsive,                    audience: Patient                },                modal: {                    type:  ,                    name: ,                    position:  ,                    enabled: ,                    displayed:                 },                search: {                    autoPosition: ,                    term: ,                    count: ,                    indication:,                    type: ,                    filterType: ,                    filterValue: ,                    filterCategory: ,                    sortByInit: ,                    origin: ,                    originURL:                 }            },            user: {                profile: {                    id: {                        crmID: ,                        transID: ,                        abbvieCustomerID: ,                        hcpAccountID: ,                        npiID: ,                        dmpID: ,                        adobeID:                     },                    attributes: {                        status: ,                        type:                     }                }            }        };    /script>            script srchttps://assets.adobedtm.com/acb96670c057/48663f28f53f/launch-450e00021d4f.min.js async>/script>        !-- **** END OF ABBVIE ANALYTICS LIBRARY **** -->title>EMRELIS™ (telisotuzumab-vedotin) – Official Patient Site/title>/head>                            body class ind-nsclc>    	div classabbv-content>				                                            div classnewpar new section>/div>                            div classpar iparys_inherited>                /div>        		div classabbv-content-container data-anim-top0 data-anim-btm0>				div>                            div classheader-v2 parbase>header classabbv-header-v2    abbv-indication-swap search-box-classic data-stick-offset0> !-- Skip Navigation --> a href#main-content classabbv-skip-to-main-content sr-only>Skip to Main content/a>		div classabbv-header-v2-utility-navigation abbv-navigation>		nav aria-labelUtility Navigation>			ul rolemenubar>				li rolenone>                                                                                          				a data-digitaldata{digitalData:{page:{component:{l10title:,name:Utility Navigation,position:header,type:menu,title:Stay Up To Date},link:{displayTitle:Sign Up Stay Up To Date,name:Stay Up To Date,type:internal,url:/content/emrelis/en-us/sign-up},interaction:{name:Sign Up Stay Up To Date,id:abbv-utilitynavigation-1927615256-0,type:menu,tags:},mva:{},menu:{level:1},content:{name:,type:,title:}}}} rolemenuitem class    i-b nav-tier1    href/sign-up target_self data-linktypeinternal>span classd-block d-lg-none>Sign Up /span>span classd-none d-lg-block>Stay Up To Date/span>/a>	                                                   /li>			/ul>		/nav>	/div>	div classabbv-header-content-container>		div classabbv-header-v2-content >			div classabbv-header-v2-left>                				    																a data-digitaldata{digitalData:{page:{component:{l10title:,name:Logo,position:header,type:link,title:emrelis logo},link:{displayTitle:Emrelis Logo,name:emrelis logo,type:internal,url:/},interaction:{name:emrelis logo,id:abbv-logo-1403555708-1,type:link,tags:},mva:{},menu:{},content:{name:,type:,title:}}}} href/>							img titleEmrelis Logo altEmrelis logo src/content/dam/emrelis/images/homepage/Emrelis-logo_r0_allviews.svg/>/img>								/a>								                			/div>			div classabbv-header-v2-right>				            div class abbv-link-list horizontal data-highlight-currenttrue>                  ul>                     /ul>      /div>   									div classutil-icons-container>													div classabbv-header-util idabbv-guest-user>																							/div> 							div classabbv-header-util idabbv-logged-user>								 															/div>						                  							                          div classabbv-header-util idabbv-search-util>															/div>							div classabbv-header-util idabbv-menu-toggle>								div classabbv-header-v2-mobile-primary-navigation tabindex0 aria-labelnavigation menu rolebutton aria-expandedfalse>									span classline>/span>									span classline>/span>									span classline>/span>								/div>							/div>						/div>					/div>			/div>		/div>	div classabbv-header-v2-primary-navigation abbv-navigation>   				nav aria-labelMain Navigation>			ul rolemenu>			 				li rolenone>                                                   				a data-digitaldata{digitalData:{page:{component:{l10title:,name:Primary Navigation,position:header,type:menu,title:Prescribing information},link:{displayTitle:Prescribing information,name:Prescribing information,type:download,url:https://www.rxabbvie.com/pdf/emrelis_pi.pdf},interaction:{name:Prescribing information,id:abbv-primarynavigation-1936924478,type:menu,tags:},mva:{},menu:{level:1},content:{name:,type:,title:}}}} rolemenuitem relnofollow hrefhttps://www.rxabbvie.com/pdf/emrelis_pi.pdf target_blank>Prescribing information/a>	                     /li>			 				li rolenone>                                                   				a data-digitaldata{digitalData:{page:{component:{l10title:,name:Primary Navigation,position:header,type:menu,title:Medication Guide},link:{displayTitle:Medication Guide,name:Medication Guide,type:download,url:https://www.rxabbvie.com/pdf/emrelis_medguide.pdf},interaction:{name:Medication Guide,id:abbv-primarynavigation-1936924479,type:menu,tags:},mva:{},menu:{level:1},content:{name:,type:,title:}}}} rolemenuitem relnofollow hrefhttps://www.rxabbvie.com/pdf/emrelis_medguide.pdf target_blank>Medication Guide/a>	                     /li>			 				li rolenone>                                                   				a data-digitaldata{digitalData:{page:{component:{l10title:,name:Primary Navigation,position:header,type:menu,title:US Healthcare Professional Website},link:{displayTitle:US Healthcare Professional Website,name:US Healthcare Professional Website,type:external,url:https://www.emrelishcp.com},interaction:{name:US Healthcare Professional Website,id:abbv-primarynavigation-1936924480,type:menu,tags:},mva:{},menu:{level:1},content:{name:,type:,title:}}}} rolemenuitem relnofollow hrefhttps://www.emrelishcp.com target_blank>US Healthcare Professional Website/a>	                     /li>						/ul>    		/nav>        	/div>/header>/div>    /div>				section rolemain>            div classcontainer parbase>    div classabbv-container abv-custom-bgcolor-primary-green pt-20 pt-md-60 pb-20 pb-md-60 border-bottom-gradient-secondary-gold>                    div classimage-text-v2 parbase>    !-- New Structure -->    div class abbv-image-text-v2 abbv-image-swap>        div classabbv-image-content-container-v2>                                        picture>                    source media(min-width: 985px) srcset/content/dam/emrelishcp/images/homepage/header-desktop.png classabbv-image-text-img abbv-image-text-img-large height233 width2160/>                    source media(min-width: 601px) and (max-width: 984px) srcset/content/dam/emrelishcp/images/homepage/header-desktop.png classabbv-image-text-img abbv-image-text-img-medium height233 width2160/>                    source media(max-width: 600px) srcset/content/dam/emrelishcp/images/homepage/header-mobile.png classabbv-image-text-img abbv-image-text-img-small height233 width1125/>                    img src/content/dam/emrelishcp/images/homepage/header-desktop.png alt height233 width2160 loadinglazy/>                                           /picture>                    /div>            /div>/div>    /div>        script typetext/javascript src/etc.clientlibs/common-elements/v1/components/content/container/clientlib-component.min.3dc16ed923c3d5068b5e6ea752932943.js defer>/script>/div>            div classcontainer parbase>    div classabbv-container >                    div classghost>/div>            div classcontainer parbase>    div classabbv-container abv-custom-bgcolor-cream>                    div classcta parbase>                                                                        	a data-digitaldata{digitalData:{page:{link:{name:,displayTitle:\u003cspan class\u003d\mr-10 font-10px line-height-20px align-nav-arrows\\u003e◀\u003c/span\u003eAbout EMRELIS \u003cspan class\u003d\ml-10 font-10px line-height-20px align-nav-arrows\\u003e▶\u003c/span\u003e,type:internal,url:},component:{type:content,l10title:,title:,name:CTA,position:content},content:{},interaction:{type:,name:\u003cspan class\u003d\mr-10 font-10px line-height-20px align-nav-arrows\\u003e◀\u003c/span\u003eAbout EMRELIS \u003cspan class\u003d\ml-10 font-10px line-height-20px align-nav-arrows\\u003e▶\u003c/span\u003e,id:abbv-cta-141757024,tags:},menu:{}}}} class   abbv-icon-dehaze abbv-button-plain i-a anchors-menu anchors-menu--trigger d-flex flex-justify_center p-10 mr-10 font-weight-bold d-md-none abv-custom-txtcolor-primary-green custom-icon-size-menu  rolelink aria-label◀About EMRELIS ▶ tabindex0 target_self data-linktypeinternal aria-hiddenfalse>span classmr-10 font-10px line-height-20px align-nav-arrows>◀/span>About EMRELIS span classml-10 font-10px line-height-20px align-nav-arrows>▶/span>/a>                                                    /div>            div classflexbox parbase>			        		div classabbv-flex-container no-gutters flex-column flex-md-row m-auto flex-wrap-wrap flex-md-align_items_center max-width-content pt-15 pb-15 p-md-0 pl-md-15 pr-md-15 anchors-menu--target d-none d-md-flex          >							                					div classabbv-flex-item d-flex flex-justify_center        >                    div classcta parbase>                                                                        	a data-digitaldata{digitalData:{page:{link:{name:,displayTitle:About EMRELIS,type:internal,url:#about-emrelis},component:{type:content,l10title:,title:,name:CTA,position:content},content:{},interaction:{type:,name:About EMRELIS,id:abbv-cta-1763520462,tags:},menu:{}}}} class    abbv-button-plain  anchors-menu--close-trigger p-15 text-nowrap font-14px d-flex d-md-none abv-custom-txtcolor-primary-green abbv-jump-link rolelink aria-labelAbout EMRELIS href#about-emrelis target_self data-linktypeinternal aria-hiddenfalse>About EMRELIS/a>                                                    /div>            div classcta parbase>                                                                        	a data-digitaldata{digitalData:{page:{link:{name:About EMRELIS,displayTitle:About EMRELIS,type:internal,url:#about-emrelis},component:{type:content,l10title:,title:About EMRELIS,name:CTA,position:content},content:{},interaction:{type:,name:About EMRELIS,id:abbv-cta-1205454940,tags:},menu:{}}}} class    abbv-button-plain  text-nowrap font-14px emrelis-button-primary-green font-weight-bold d-none d-md-flex mt-20 mb-20 anchors-menu--close-trigger abbv-jump-link rolelink aria-labelAbout EMRELIS href#about-emrelis target_self data-linktypeinternal aria-hiddenfalse>About EMRELIS/a>                                                    /div>/div>                							                					div classabbv-flex-item  font-weight-md-bold d-flex flex-justify_center        >                    div classcta parbase>                                                                        	a data-digitaldata{digitalData:{page:{link:{name:Results,displayTitle:Results,type:internal,url:#clinical-trial-results},component:{type:content,l10title:,title:Results,name:CTA,position:content},content:{},interaction:{type:,name:Results,id:abbv-cta-1711013565,tags:},menu:{}}}} class    abbv-button-plain  anchors-menu--close-trigger p-15 text-nowrap abv-custom-txtcolor-primary-green font-14px abbv-jump-link rolelink aria-labelResults href#clinical-trial-results target_self data-linktypeinternal aria-hiddenfalse>Results/a>                                                    /div>/div>                							                					div classabbv-flex-item  font-weight-md-bold d-flex flex-justify_center        >                    div classcta parbase>                                                                        	a data-digitaldata{digitalData:{page:{link:{name:Side Effects,displayTitle:Side Effects,type:internal,url:#side-effects},component:{type:content,l10title:,title:Side Effects,name:CTA,position:content},content:{},interaction:{type:,name:Side Effects,id:abbv-cta-2078395106,tags:},menu:{}}}} class    abbv-button-plain  anchors-menu--close-trigger p-15 text-nowrap abv-custom-txtcolor-primary-green font-14px abbv-jump-link rolelink aria-labelSide Effects href#side-effects target_self data-linktypeinternal aria-hiddenfalse>Side Effects/a>                                                    /div>/div>                							                					div classabbv-flex-item  font-weight-md-bold d-flex flex-justify_center        >                    div classcta parbase>                                                                        	a data-digitaldata{digitalData:{page:{link:{name:How EMRELIS works,displayTitle:How EMRELIS Works,type:internal,url:#how-emrelis-works},component:{type:content,l10title:,title:How EMRELIS works,name:CTA,position:content},content:{},interaction:{type:,name:How EMRELIS Works,id:abbv-cta-1572836481,tags:},menu:{}}}} class    abbv-button-plain  anchors-menu--close-trigger p-15 text-nowrap abv-custom-txtcolor-primary-green font-14px abbv-jump-link rolelink aria-labelHow EMRELIS Works href#how-emrelis-works target_self data-linktypeinternal aria-hiddenfalse>How EMRELIS Works/a>                                                    /div>/div>                							                					div classabbv-flex-item  font-weight-md-bold d-flex flex-justify_center        >                    div classcta parbase>                                                                        	a data-digitaldata{digitalData:{page:{link:{name:Taking EMRELIS,displayTitle:Taking EMRELIS,type:internal,url:#taking-emrelis},component:{type:content,l10title:,title:Taking EMRELIS,name:CTA,position:content},content:{},interaction:{type:,name:Taking EMRELIS,id:abbv-cta-1067277856,tags:},menu:{}}}} class    abbv-button-plain  anchors-menu--close-trigger p-15 text-nowrap abv-custom-txtcolor-primary-green font-14px abbv-jump-link rolelink aria-labelTaking EMRELIS href#taking-emrelis target_self data-linktypeinternal aria-hiddenfalse>Taking EMRELIS/a>                                                    /div>/div>                							                					div classabbv-flex-item  font-weight-md-bold d-flex flex-justify_center        >                    div classcta parbase>                                                                        	a data-digitaldata{digitalData:{page:{link:{name:Patient Support,displayTitle:Patient Support,type:internal,url:#patient-support},component:{type:content,l10title:,title:Patient Support,name:CTA,position:content},content:{},interaction:{type:,name:Patient Support,id:abbv-cta-561719231,tags:},menu:{}}}} class    abbv-button-plain  anchors-menu--close-trigger p-15 text-nowrap abv-custom-txtcolor-primary-green font-14px abbv-jump-link rolelink aria-labelPatient Support href#patient-support target_self data-linktypeinternal aria-hiddenfalse>Patient Support/a>                                                    /div>/div>                					/div>	/div>            div classactions parbase> script>    document.addEventListener(DOMContentLoaded, function(e) {        abbvAction.addAction(.anchors-menu--trigger, click, toggleClass|d-none|.anchors-menu--target);    });/script>/div>            div classactions parbase> script>    document.addEventListener(DOMContentLoaded, function(e) {        abbvAction.addAction(.anchors-menu--close-trigger, click, toggleClass|d-none|.anchors-menu--target);    });/script>/div>    /div>        /div>            div classflexbox parbase>			a idabout-emrelis>/a>        		div classabbv-flex-container abv-custom-bgcolor-primary-green pt-45 pt-md-80 pb-60          >							                					div classabbv-flex-item max-width-1200 m-auto p-0 pl-15 pr-15        >                    div classtitles parbase>div classabbv-title >    h2 classabv-custom-txtcolor-secondary-gold font-16px font-md-22px font-lg-28px  mb-5 mb-md-10>ABOUT EMRELIS/h2>/div>/div>            div classrich-text>        div classabbv-rich-text  abbv-rich-text-common>        hr classabv-custom-bgcolor-secondary-gold mt-5 mb-25 mb-md-40 />    /div>/div>            div classimage-text-v2 parbase>    !-- New Structure -->    div classmax-width-img-50 max-width-md-img-80 icon-text abv-custom-txtcolor-white font-17px font-md-22px flex-column flex-md-row  abbv-image-text-v2 abbv-image-scale>        div classabbv-image-content-container-v2>                            img src/content/dam/emrelis/images/homepage/human-lungs-icon_r0_allviews.svg altIcon of human lungs loadinglazy/>                                                    /div>                    div classabbv-image-text-content-container-v2  abbv-image-text-out>                div classabbv-image-text-content-v2>                    div classabbv-image-text-display-v2>                        div classabbv-stretched-card-body>                            p classmt-0 mb-0 ml-0 ml-md-15 mt-md-n20>EMRELIS is a prescription medicine used to treat adults with non-squamous non-small cell lung cancer (NSCLC) that has spread to areas near the lungs or to other parts of the body, span classfont-weight-bold>and/span> whose tumors have high c-Met protein overexpression,* span classfont-weight-bold>and/span> who received a prior treatment. Your healthcare provider will perform a test to make sure EMRELIS is right for you./p>                                                    /div>                    /div>                /div>            /div>            /div>/div>            div classrich-text>        div classabbv-rich-text font-17px font-md-22px line-height-22px line-height-md-32px abv-custom-txtcolor-white ml-md-90 abbv-rich-text-common>        p classm-0>EMRELIS is approved based on response rate and how long patients’ responses lasted. A study is ongoing to confirm the clinical benefit of EMRELIS./p>p classmt-20 mb-0>Click a href#how-emrelis-works classfont-weight-bold abv-custom-txtcolor-white text-underline>here/a> to learn how EMRELIS works. It is not known if EMRELIS is safe and effective in children./p>    /div>/div>            div classflexbox parbase>			        		div classabbv-flex-container flex-column flex-md-row mt-25 mt-md-80          >							                					div classabbv-flex-item m-0 p-0 mr-md-20 mr-lg-80        >                    div classimage-text-v2 parbase>    !-- New Structure -->    div classmax-width-img-50 max-width-md-img-80 abv-custom-txtcolor-white font-17px line-height-22px flex-row abbv-image-text-v2 abbv-image-scale>        div classabbv-image-content-container-v2>                            img src/content/dam/emrelis/images/homepage/c-met-protein-overexpression-icon_r0_allviews.svg altc-met protein overexpression icon width75 loadinglazy/>                                                    /div>                    div classabbv-image-text-content-container-v2 top-right abbv-image-text-out>                div classabbv-image-text-content-v2>                    div classabbv-image-text-display-v2>                        div classabbv-stretched-card-body>                            p classml-10 ml-md-20 pt-0 mt-n20>c-Met protein overexpression is a type of MET aberration where there is an excess of the c-Met protein on the surface of cells./p>                                                    /div>                    /div>                /div>            /div>            /div>/div>/div>                							                					div classabbv-flex-item m-0 p-0        >                    div classimage-text-v2 parbase>    !-- New Structure -->    div classmax-width-img-50 max-width-md-img-80 abv-custom-txtcolor-white font-17px line-height-22px flex-row abbv-image-text-v2 abbv-image-scale>        div classabbv-image-content-container-v2>                            img src/content/dam/emrelis/images/homepage/microscope-icon_r0_allviews.svg altIcon of a microscope displayed within a circular yellow background. loadinglazy/>                                                    /div>                    div classabbv-image-text-content-container-v2 top-right abbv-image-text-out>                div classabbv-image-text-content-v2>                    div classabbv-image-text-display-v2>                        div classabbv-stretched-card-body>                            p classml-10 ml-md-15 pt-0 mt-n20>IHC is an established testing method in NSCLC. MET IHC test is the one available to determine if a patient has high c-Met protein overexpression./p>                                                    /div>                    /div>                /div>            /div>            /div>/div>/div>                					/div>	/div>            div classflexbox parbase>			        		div classabbv-flex-container max-width-1024 m-auto emrelis-homepage-gradient-card emrelis-homepage-gradient-card--primary-green mt-md-40          >							                					div classabbv-flex-item pl-20 pr-20 pl-md-60 pr-md-60 pl-lg-80 pr-lg-80 pt-25 pb-25        >                    div classrich-text>        div classabbv-rich-text abv-custom-txtcolor-white text-center font-17px font-md-22px abbv-rich-text-common>        p classmt-0>span stylebackground-color: transparent;>b>Talk to your doctor about testing for high /b>/span>b>span classtext-nowrap>c-Met/span>span stylebackground-color: transparent;> protein overexpression to help determine if treatment with EMRELIS may be right for you./span>/b>/p>    /div>/div>/div>                					/div>	/div>            div classrich-text>        div classabbv-rich-text font-13px font-md-15px line-height-17px abv-custom-txtcolor-white mt-md-85 mt-20 abbv-rich-text-common>        p classmb-5>*High c-Met protein overexpression is determined by an immunohistochemistry (IHC) test and defined as ≥50% of tumor cells with strong (3+) staining./p>    /div>/div>/div>                					/div>	/div>            div classflexbox parbase>			a idclinical-trial-results>/a>        		div classabbv-flex-container abv-custom-bgcolor-cream pt-30 pt-md-40          >							                					div classabbv-flex-item max-width-1200 m-auto p-0 pl-15 pr-15 abv-custom-txtcolor-primary-green        >                    div classimage-text-v2 parbase>    !-- New Structure -->    div class mb-md-65 mb-45 abbv-image-text-v2 abbv-image-swap>        div classabbv-image-content-container-v2>                                        picture>                    source media(min-width: 985px) srcset/content/dam/emrelishcp/images/homepage/section-divider_r0_desktop.png classabbv-image-text-img abbv-image-text-img-large height40 width2408/>                    source media(min-width: 601px) and (max-width: 984px) srcset/content/dam/emrelishcp/images/homepage/section-divider_r0_desktop.png classabbv-image-text-img abbv-image-text-img-medium height40 width2408/>                    source media(max-width: 600px) srcset/content/dam/emrelishcp/images/homepage/section-divider_r0_mobile.png classabbv-image-text-img abbv-image-text-img-small height41 width662/>                    img src/content/dam/emrelishcp/images/homepage/section-divider_r0_desktop.png alt height40 width2408 loadinglazy/>                                           /picture>                    /div>            /div>/div>            div classtitles parbase>div classabbv-title >    h2 classfont-16px font-md-22px font-lg-28px  mb-5 mb-md-10>RESULTS/h2>/div>/div>            div classrich-text>        div classabbv-rich-text  abbv-rich-text-common>        hr classmt-0 mb-30 mt-md-0 mb-md-60 abv-custom-bgcolor-primary-green  />    /div>/div>            div classtitles parbase>div classabbv-title >    h3 classfont-weight-medium font-22px font-md-30px font-lg-40px line-height-28px line-height-md-55px>How EMRELIS performed in a clinical trial/h3>/div>/div>            div classrich-text>        div classabbv-rich-text font-md-22px font-17px line-height-22px line-height-md-32px font-weight-semiregular abbv-rich-text-common>        p classmt-20 mt-md-50 mb-30 mb-md-55>EMRELIS was studied in the LUMINOSITY clinical trial with 84 adults who were previously treated for late-stage non-squamous NSCLC with high c-Met protein overexpression.*/p>    /div>/div>            div classflexbox parbase>			        		div classabbv-flex-container flex-column flex-md-row flex-align_items_center flex-md-align_items_start          >							                					div classabbv-flex-item m-0 p-0 max-width-md-135 max-width-md-211 mr-md-40 mb-20 mb-md-0        >                    div classimage-text-v2 parbase>    !-- New Structure -->    div classmax-width-img-125 max-width-md-img-211 text-center abbv-image-text-v2 abbv-image-scale>        div classabbv-image-content-container-v2>                            img src/content/dam/emrelis/images/homepage/pie-chart-icon_r0_allviews.svg altPie chart displaying 29% highlighted in yellow, representing a segment of the whole loadinglazy/>                                                    /div>            /div>/div>            div classrich-text>        div classabbv-rich-text max-width-md-120 m-auto text-center text-md-left font-14px font-md-16px line-height-22px abbv-rich-text-common>        p>Partialbr classd-none d-md-inline />Response: 35%/p>p>Completebr classd-none d-md-inline />Response: 0%/p>    /div>/div>/div>                							                					div classabbv-flex-item m-0 p-0        >                    div classtitles parbase>div classabbv-title >    h3 classfont-weight-medium font-22px font-md-30px font-lg-40px>Overall responsesup classfont-22px font-lg-40px line-height-default>/sup>: 35% saw tumors shrink/h3>/div>/div>            div classrich-text>        div classabbv-rich-text font-weight-semiregular abbv-rich-text-common>        p classfont-17px line-height-22px font-md-22px line-height-md-32px mb-0>Overall response is a measure of all people who had either a complete or partial response./p>p classfont-17px line-height-22px font-md-22px line-height-md-32px mb-0>Out of the 84 people treated with EMRELIS, span classfont-weight-bold>29 people achieved a partial response,/span> meaning a reduction in tumor size or presence by at least 30%./p>p classfont-17px line-height-22px font-md-22px line-height-md-32px mt-15 mb-0>A complete response is defined as the patient having no signs of cancer on a follow-up scan. span classfont-weight-bold>No one had a complete response./span>/p>    /div>/div>/div>                					/div>	/div>            div classflexbox parbase>			        		div classabbv-flex-container mt-md-30 mt-40          >							                					div classabbv-flex-item m-0 p-0        >                    div classflexbox parbase>			        		div classabbv-flex-container flex-column           >							                					div classabbv-flex-item m-0 p-0        >                    div classrich-text>        div classabbv-rich-text font-weight-bold font-17px line-height-22px font-md-22px line-height-md-32px mb-30 text-left abbv-rich-text-common>        p classmt-0 ml-lg-100 pl-lg-150 m-auto>span classd-block font-22px font-lg-40px mb-10 mb-lg-30>Duration of response:/span>Of the 29 people who responded to EMRELIS, the decrease in their tumor size lasted for a mediansup classline-height-default font-14px>†/sup> of 7.2 months./p>    /div>/div>            div classimage-text-v2 parbase>    !-- New Structure -->    div classmax-width-img-160 max-width-160 m-auto mb-25 mb-md-30 abbv-image-text-v2 abbv-image-scale>        div classabbv-image-content-container-v2>                            img src/content/dam/emrelis/images/homepage/alendar-icon_r0_allviews.svg altYellow calendar icon with '7.2 months' written in the center, representing a time duration loadinglazy/>                                                    /div>            /div>/div>/div>                							                					div classabbv-flex-item m-0 p-0        >                    div classcontainer parbase>    div classabbv-container >                    div classrich-text>        div classabbv-rich-text font-weight-bold font-17px line-height-22px font-md-22px line-height-md-32px m-auto ml-lg-100 pl-lg-150 abbv-rich-text-common>        p classmt-0>Of the 29 people who responded to EMRELIS:/p>    /div>/div>    /div>        /div>            div classflexbox parbase>			        		div classabbv-flex-container no-gutters flex-column flex-md-row ml-lg-100 pl-lg-150 m-auto          >							                					div classabbv-flex-item mr-15 mr-md-30 mr-lg-60        >                    div classrich-text>        div classabbv-rich-text font-weight-semiregular font-14px line-height-22px font-md-22px line-height-md-32px max-width-lg-375 full-bullet abbv-rich-text-common>        ul classm-0 pl-20>li>span classfont-weight-bold>59%,/span> or 17 responders, had their response last span classfont-weight-bold>6 months/span> or longer/li>/ul>    /div>/div>/div>                							                					div classabbv-flex-item         >                    div classrich-text>        div classabbv-rich-text font-weight-semiregular font-14px line-height-22px font-md-22px line-height-md-32px ml-md-30 max-width-lg-375 full-bullet abbv-rich-text-common>        ul classm-0 pl-20>li>span classfont-weight-bold>21%,/span> or 6 responders, had their response last span classfont-weight-bold>12 months/span> or longer/li>/ul>    /div>/div>/div>                					/div>	/div>/div>                					/div>	/div>            div classrich-text>        div classabbv-rich-text text-left font-17px font-lg-22px line-height-22px font-weight-semiregular max-width-lg-940 mt-40 mt-lg-80 mb-40 mb-lg-70 mr-40 mr-md-0 abbv-rich-text-common>        p>Your results with EMRELIS may vary. Talk to your healthcare team if you have questions./p>    /div>/div>            div classrich-text>        div classabbv-rich-text font-weight-semiregular font-13px font-md-14px mt-20 mt-md-25 line-height-16px  abbv-rich-text-common>        div>p classmt-0 mb-5 d-inline_block>span classpos-absolute ml-n5>*/span>span>High c-Met protein overexpression is determined by an immunohistochemistry (IHC) test and defined as ≥50% of tumor cells with strong (3+) staining./span>/p>/div>div>p classmt-0 mb-0 d-inline_block>span classpos-absolute ml-n5 mt-n5>sup>†/sup>/span>span>Middle value in the entire set of response times./span>/p>/div>    /div>/div>/div>                					/div>	/div>/div>                					/div>	/div>            div classflexbox parbase>			a idside-effects>/a>        		div classabbv-flex-container abv-custom-bgcolor-cream pt-35 pb-85 pt-md-70          >							                					div classabbv-flex-item max-width-1200 m-auto p-0 pl-15 pr-15 abv-custom-txtcolor-primary-green        >                    div classtitles parbase>div classabbv-title >    h2 classfont-16px font-md-22px font-lg-28px  mb-5 mb-md-10>SIDE EFFECTS/h2>/div>/div>            div classrich-text>        div classabbv-rich-text  abbv-rich-text-common>        hr classmt-0 mb-30 mt-md-0 mb-md-60 abv-custom-bgcolor-primary-green  />    /div>/div>            div classflexbox parbase>			        		div classabbv-flex-container           >							                					div classabbv-flex-item p-0 m-0        >                    div classtitles parbase>div classabbv-title >    h3 classfont-weight-medium font-22px font-md-30px font-lg-40px mb-20 mb-md-50>What is the most important information I should know about EMRELIS?/h3>/div>/div>            div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular abbv-rich-text-common>        p classmt-0 mb-20>span classfont-weight-bold>EMRELIS can cause serious side effects, including:/span>/p>div classfull-bullet>ul classpl-20 mb-15 bold-bullet>li>span classfont-weight-bold>Nerve problems in your hands or feet (peripheral neuropathy). /span>Nerve problems are common during treatment with EMRELIS and can also be severe. Tell your healthcare provider if you develop any new or worsening signs or symptoms of nerve problems, including:/li>/ul>/div>    /div>/div>            div classflexbox parbase>			        		div classabbv-flex-container flex-column flex-md-row no-gutters          >							                					div classabbv-flex-item max-width-md-500        >                    div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular circle-bullet abbv-rich-text-common>        ul classm-0>li>numbness/li>li>tingling/li>li>burning sensation/li>/ul>    /div>/div>/div>                							                					div classabbv-flex-item         >                    div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular circle-bullet abbv-rich-text-common>        ul classm-0>li>pain or discomfort/li>li>muscle weakness/li>li>difficulty walking/li>/ul>    /div>/div>/div>                					/div>	/div>            div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular mt-15 mb-0 abbv-rich-text-common>        div classfull-bullet>ul classpl-20 mt-0 mb-15 bold-bullet>li>span classfont-weight-bold>Lung problems./span> EMRELIS can cause lung problems that may be severe, life-threatening or that may lead to death. Tell your healthcare provider right away if you develop new or worsening lung symptoms, including:/li>/ul>/div>    /div>/div>            div classflexbox parbase>			        		div classabbv-flex-container flex-column flex-md-row no-gutters          >							                					div classabbv-flex-item max-width-md-500        >                    div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular circle-bullet abbv-rich-text-common>        ul classm-0>li>cough/li>li>trouble breathing or shortness of breath/li>/ul>    /div>/div>/div>                							                					div classabbv-flex-item         >                    div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular circle-bullet abbv-rich-text-common>        ul classm-0>li>fever/li>li>wheezing/li>/ul>    /div>/div>/div>                					/div>	/div>            div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular mt-15 mb-0 abbv-rich-text-common>        div classfull-bullet>ul classpl-20 m-0 mb-15 bold-bullet>li>span classfont-weight-bold>Eye problems./span> Your healthcare provider may send you to an eye care professional to check your eyes if you develop eye problems. Tell your healthcare provider right away if you develop any new or worsening eye problems or vision changes, including:/li>/ul>/div>    /div>/div>            div classflexbox parbase>			        		div classabbv-flex-container flex-column flex-md-row no-gutters          >							                					div classabbv-flex-item max-width-md-500        >                    div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular circle-bullet abbv-rich-text-common>        ul classm-0>li>blurred vision/li>li>dry eyes/li>li>sensitivity to light/li>/ul>    /div>/div>/div>                							                					div classabbv-flex-item         >                    div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular circle-bullet abbv-rich-text-common>        ul classm-0>li>eye pain or swelling/li>li>eye redness/li>/ul>    /div>/div>/div>                					/div>	/div>            div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular mt-15 mb-0 abbv-rich-text-common>        div classfull-bullet>ul classpl-20 m-0 mb-15 bold-bullet>li>span classfont-weight-bold>Infusion-related reactions./span> EMRELIS can cause infusion reactions that can be severe or life-threatening. Tell your healthcare provider right away if you develop any signs and symptoms of infusion reactions, including:/li>/ul>/div>    /div>/div>            div classflexbox parbase>			        		div classabbv-flex-container flex-column flex-md-row no-gutters          >							                					div classabbv-flex-item flex-col-md-6 max-width-md-500        >                    div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular circle-bullet abbv-rich-text-common>        ul classm-0>li>itching or rash/li>li>shortness of breath or wheezing/li>li>flushing/li>li>chest discomfort/li>li>fever/li>/ul>    /div>/div>/div>                							                					div classabbv-flex-item flex-col-md-6        >                    div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular circle-bullet abbv-rich-text-common>        ul classm-0>li>back pain/li>li>chills/li>li>headache/li>li>nausea or vomiting/li>li>feel like passing out/li>/ul>    /div>/div>/div>                					/div>	/div>            div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular mt-20 mt-md-20 abbv-rich-text-common>        p classm-0>span classfont-weight-bold>Getting medical treatment right away may help keep these problems from becoming more serious./span> Your healthcare provider will check you for these problems during your treatment with EMRELIS and may provide treatment for your side effects. Your healthcare provider may also need to change your dose, temporarily stop, or completely stop treatment with EMRELIS if you have severe side effects./p>    /div>/div>            div classtitles parbase>div classabbv-title mt-40 mt-md-55>    h3 classfont-weight-medium font-22px font-md-30px font-lg-40px>What are the possible side effects of EMRELIS?/h3>/div>/div>            div classrich-text>        div classabbv-rich-text font-17px line-height-md-22px font-md-22px line-height-md-32px font-weight-semiregular mt-25 full-bullet abbv-rich-text-common>        p classm-0>span classfont-weight-bold>EMRELIS can cause serious side effects. See “What is the most important information I should know about EMRELIS?”/span>/p>p classmt-15 mb-0>span classfont-weight-bold>The most common side effects of EMRELIS include:/span>/p>div classd-md-flex>ul classmt-10 mb-0 flex-col-md-6 max-width-md-500 pl-20>li classline-height-22px line-height-md-32px>feeling tired/li>li classline-height-22px line-height-md-32px>decreased appetite/li>/ul>ul classmt-md-10 mt-0 mb-0 flex-col-md-6 pl-20 pl-md-40>li classline-height-22px line-height-md-32px>swelling in the feet, ankles, legs or hands/li>/ul>/div>p classmt-15 mb-0>span classfont-weight-bold>The most common severe abnormal laboratory test results with EMRELIS include:/span>/p>div classmt-15 mb-0 d-flex flex-column flex-md-row>ul classm-0 flex-col-md-6 pl-20 max-width-md-500 line-height-22px line-height-md-32px>li>decreased white blood cell counts/li>li>increased blood sugar levels/li>li>increased blood liver enzyme levels/li>li>decreased blood phosphorus levels/li>/ul>ul classm-0 flex-col-md-6 pl-20 pl-md-40 line-height-22px line-height-md-32px>li>decreased blood sodium levels/li>li>decreased red blood cell counts/li>li>decreased blood calcium levels/li>/ul>/div>div classmt-15 mb-0 mb-md-0>p classm-0>EMRELIS may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility./p>p classmb-0 mt-10>These are not all the possible side effects of EMRELIS./p>p classmb-0 mt-10>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088./p>/div>    /div>/div>/div>                					/div>	/div>/div>                					/div>	/div>            div classflexbox parbase>			a idhow-emrelis-works>/a>        		div classabbv-flex-container abv-custom-bgcolor-primary-green pt-45 pb-55 pt-md-80 pb-md-60          >							                					div classabbv-flex-item max-width-1200 m-auto p-0 pl-15 pr-15 abv-custom-txtcolor-white        >                    div classtitles parbase>div classabbv-title >    h2 classabv-custom-txtcolor-secondary-gold font-16px font-md-22px font-lg-28px  mb-5 mb-md-10>HOW IT WORKS/h2>/div>/div>            div classrich-text>        div classabbv-rich-text  abbv-rich-text-common>        hr classabv-custom-bgcolor-secondary-gold mt-5 mb-25 mb-md-40 />    /div>/div>            div classtitles parbase>div classabbv-title >    h3 classfont-weight-medium font-22px font-md-30px font-lg-40px abv-custom-txtcolor-secondary-gold>How EMRELIS works/h3>/div>/div>            div classrich-text>        div classabbv-rich-text mt-25 mt-md-50 abbv-rich-text-common>        p classm-0 font-weight-bold font-17px font-md-24px font-lg-32px >EMRELIS works by targeting c-Met protein./p>p classm-0 mt-25 mt-md-20 font-17px font-md-22px line-height-22px line-height-md-32px font-weight-semiregular>EMRELIS contains the active substance telisotuzumab vedotin which is made up of a protein referred to as a monoclonal antibody which is linked to a substance called MMAE (monomethyl auristatin E) that can disrupt cell growth and trigger cell death. The monoclonal antibody recognizes cells with increased amounts of c-Met protein and delivers the MMAE to the cells./p>    /div>/div>            div classflexbox parbase>			        		div classabbv-flex-container flex-column flex-md-row mt-40 mt-md-55          >							                					div classabbv-flex-item m-0 p-0 mr-md-50 mr-lg-70 mb-90 mb-md-0         >                    div classimage-text-v2 parbase>    !-- New Structure -->    div classmax-width-img-330 max-width-md-img-370 m-auto ml-md-0 text-center text-md-left font-md-20px font-16px line-height-25px line-height-md-27px emrelis-border-img-gold emrelis-double-arrow-gold abbv-image-text-v2 abbv-image-scale>        div classabbv-image-content-container-v2>                            img src/content/dam/emrelis/images/homepage/inside-a-normal-cell_r0_allviews.svg altIllustration of c-Met protein present at low levels in a normal cell loadinglazy/>                                                    /div>                    div classabbv-image-text-content-container-v2 bottom-middle abbv-image-text-out>                div classabbv-image-text-content-v2>                    div classabbv-image-text-display-v2>                        div classabbv-stretched-card-body>                            p classmb-0 font-weight-bold text-left >span classabv-custom-txtcolor-secondary-gold>Normal Cell/span>/p>p classmt-0 mb-0 text-left>c-Met protein is normally present at low levels on certain cells./p>                                                    /div>                    /div>                /div>            /div>            /div>/div>/div>                							                					div classabbv-flex-item m-0 p-0 mr-md-50 mr-lg-70 mb-90 mb-md-0        >                    div classimage-text-v2 parbase>    !-- New Structure -->    div classmax-width-img-330 max-width-md-img-370 m-auto ml-md-0 text-center text-md-left font-md-20px font-16px line-height-25px line-height-md-27px emrelis-border-img-gold emrelis-double-arrow-gold abbv-image-text-v2 abbv-image-scale>        div classabbv-image-content-container-v2>                            img src/content/dam/emrelis/images/homepage/inside-a-cancer-cell_r0_allviews.svg altIllustration of a cancer cell showing c-Met receptors on the cell surface loadinglazy/>                                                    /div>                    div classabbv-image-text-content-container-v2 bottom-middle abbv-image-text-out>                div classabbv-image-text-content-v2>                    div classabbv-image-text-display-v2>                        div classabbv-stretched-card-body>                            p classmb-0 font-weight-bold text-left>span classabv-custom-txtcolor-secondary-gold>Cancer Cell/span>/p>p classmt-0 mb-0 text-left>In certain cancers like NSCLC, tumor cells may have c-Met protein overexpression, which can cause those cells to not only survive but grow and rapidly spread./p>                                                    /div>                    /div>                /div>            /div>            /div>/div>/div>                							                					div classabbv-flex-item m-0 p-0        >                    div classimage-text-v2 parbase>    !-- New Structure -->    div classmax-width-img-330 max-width-md-img-370 m-auto ml-md-0 text-center text-md-left font-md-20px font-16px line-height-25px line-height-md-27px emrelis-border-img-gold abbv-image-text-v2 abbv-image-scale>        div classabbv-image-content-container-v2>                            img src/content/dam/emrelis/images/homepage/cancer-cell-with-emrelis_r0_allviews.svg altIllustration of a cancer cell with EMRELIS binding to c-Met receptors and releasing anti-cancer medicine loadinglazy/>                                                    /div>                    div classabbv-image-text-content-container-v2 bottom-middle abbv-image-text-out>                div classabbv-image-text-content-v2>                    div classabbv-image-text-display-v2>                        div classabbv-stretched-card-body>                            p classmb-0 font-weight-bold text-left>span classabv-custom-txtcolor-secondary-gold>EMRELIS/span>/p>p classmt-0 mb-0 text-left>EMRELIS targets and binds to span classtext-nowrap>c-Met/span> receptors on the cell’s surface. It then enters the cell and releases a potent medicine, disrupting cell growth and triggering cell death./p>                                                    /div>                    /div>                /div>            /div>            /div>/div>            div classrich-text>        div classabbv-rich-text text-md-right font-14px mt-30 mb-n40 abbv-rich-text-common>        p>EMRELIS can also harm normal cells./p>p>Illustrative purposes only./p>    /div>/div>/div>                					/div>	/div>/div>                					/div>	/div>            div classflexbox parbase>			a idtaking-emrelis>/a>        		div classabbv-flex-container abv-custom-bgcolor-cream pt-30 pt-md-40          >							                					div classabbv-flex-item max-width-1200 m-auto p-0 pl-15 pr-15 abv-custom-txtcolor-primary-green        >                    div classimage-text-v2 parbase>    !-- New Structure -->    div classmb-md-65 mb-45 abbv-image-text-v2 abbv-image-swap>        div classabbv-image-content-container-v2>                                        picture>                    source media(min-width: 985px) srcset/content/dam/emrelishcp/images/homepage/section-divider_r0_desktop.png classabbv-image-text-img abbv-image-text-img-large height40 width2408/>                    source media(min-width: 601px) and (max-width: 984px) srcset/content/dam/emrelishcp/images/homepage/section-divider_r0_desktop.png classabbv-image-text-img abbv-image-text-img-medium height40 width2408/>                    source media(max-width: 600px) srcset/content/dam/emrelishcp/images/homepage/section-divider_r0_mobile.png classabbv-image-text-img abbv-image-text-img-small height41 width662/>                    img src/content/dam/emrelishcp/images/homepage/section-divider_r0_desktop.png alt height40 width2408 loadinglazy/>                                           /picture>                    /div>            /div>/div>            div classtitles parbase>div classabbv-title >    h2 classfont-16px font-md-22px font-lg-28px  mb-5 mb-md-10>TAKING EMRELIS/h2>/div>/div>            div classrich-text>        div classabbv-rich-text  abbv-rich-text-common>        hr classmt-0 mb-30 mb-md-60 abv-custom-bgcolor-primary-green  />    /div>/div>            div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular full-bullet-full full-bullet abbv-rich-text-common>        p classfont-weight-bold mb-0>Before receiving EMRELIS, tell your healthcare provider about all of your medical conditions, including if you:/p>ul classlist-style-type-disc pl-20 mt-10 mb-0>li>have a history of nerve problems/li>li>have lung or breathing problems other than your lung cancer/li>li>have eye problems/li>li>have liver problems/li>li>are pregnant or plan to become pregnant. EMRELIS can harm your unborn baby./li>/ul>div classcircle-bullet ml-20>p classfont-weight-bold m-0>Females who are able to become pregnant:/p>ul classcircle-bullet m-0 pl-20>li>Your healthcare provider should do a pregnancy test before you start treatment with EMRELIS./li>li>You should use effective birth control (contraception) during treatment and for 2 months after your last dose of EMRELIS./li>li>Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EMRELIS./li>/ul>p classfont-weight-bold m-0>Males with female partners who are able to become pregnant:/p>ul classcircle-bullet m-0 pl-20>li>You should use an effective birth control during treatment and for 4 months after your last dose of EMRELIS./li>/ul>/div>ul classlist-style-type-disc pl-20 m-0>li>are breastfeeding or plan to breastfeed. It is not known if EMRELIS passes into your breast milk. Do not breastfeed during treatment with EMRELIS and for 1 month after the last dose./li>/ul>p classmt-20 mb-0>span classfont-weight-bold>Tell your healthcare provider about all the medicines you take/span>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking certain medicines with EMRELIS may increase your risk of side effects./p>    /div>/div>            div classtitles parbase>div classabbv-title mt-25>    h3 classfont-weight-medium font-22px font-md-30px font-lg-40px>How will I receive EMRELIS?/h3>/div>/div>            div classrich-text>        div classabbv-rich-text font-17px line-height-22px font-md-22px line-height-md-32px font-weight-semiregular mt-20 full-bullet abbv-rich-text-common>        ul classm-0 pl-20  line-height-22px line-height-md-32px>li>Your healthcare provider will give you EMRELIS into your vein through an intravenous (IV) line over 30 minutes./li>li>EMRELIS is given 1 time every 2 weeks./li>li>Your healthcare provider will decide how many infusions of EMRELIS you will receive./li>/ul>    /div>/div>            div classrich-text>        div classabbv-rich-text font-10px font-md-13px mt-65 mb-25 mt-md-100 mb-md-100 abbv-rich-text-common>        p classm-0>IHCimmunohistochemistry; NSCLCnon-small cell lung cancer./p>    /div>/div>/div>                					/div>	/div>            div classflexbox parbase>			a idpatient-support>/a>        		div classabbv-flex-container abv-custom-bgcolor-primary-green pt-45 pt-md-80 pb-50          >							                					div classabbv-flex-item m-auto max-width-1200 abv-custom-txtcolor-white font-weight-semiregular p-0 pl-15 pr-15        >                    div classtitles parbase>div classabbv-title >    h2 classfont-16px font-md-22px font-lg-28px abv-custom-txtcolor-secondary-gold mb-5 mb-md-10>PATIENT SUPPORT/h2>/div>/div>            div classrich-text>        div classabbv-rich-text  abbv-rich-text-common>        hr classabv-custom-bgcolor-secondary-gold mt-5 mb-25 mb-md-40 />    /div>/div>            div classtitles parbase>div classabbv-title mt-55 mt-md-0>    h3 classfont-weight-medium font-22px font-md-30px font-lg-40px abv-custom-txtcolor-secondary-gold>EMRELIS Support Services/h3>/div>/div>            div classrich-text>        div classabbv-rich-text font-17px font-md-22px line-height-22px line-height-md-32px abbv-rich-text-common>        p classmt-25 mb-25>EMRELIS Support Services is here to help you and your provider navigate your treatment journey./p>p classmb-50>Your provider can work directly with EMRELIS Support Services to understand your insurance coverage for EMRELIS and determine co-pay assistance eligibility./p>    /div>/div>            div classtitles parbase>div classabbv-title >    h3 classfont-weight-medium font-22px font-md-30px font-lg-40px abv-custom-txtcolor-secondary-gold>Commercially insured patients could pay as little as $0 for their medicationsup classline-height-default font-14px font-lg-22px font-weight-bold>‡/sup>/h3>/div>/div>            div classrich-text>        div classabbv-rich-text font-17px font-md-22px line-height-22px line-height-md-32px abbv-rich-text-common>        p classmb-50>Your provider can help you enroll in EMRELIS Support Services to receive co-pay assistance. Make sure you ask your provider to help you enroll. Once enrolled, you won’t need to do anything to receive this assistance./p>    /div>/div>            div classtitles parbase>div classabbv-title >    h3 classfont-weight-medium font-22px font-md-30px font-lg-40px abv-custom-txtcolor-secondary-gold>MyAbbVie Assist/h3>/div>/div>            div classrich-text>        div classabbv-rich-text font-17px font-md-22px line-height-22px line-height-md-32px abbv-rich-text-common>        p classmb-20 mb-md-0>If you are having difficulty paying for your medicine, AbbVie may be able to help./p>p classm-0>Visit a classabv-custom-txtcolor-secondary-gold text-underline data-digitaldata{"digitalData":{"page":{"link":{"name":"","displayTitle":"AbbVie.com/PatientAccessSupport","type":"external","url":"https://www.abbvie.com/PatientAccessSupport"},"component":{"type":"content","l10title":"","title":"Patient Support","name":"RTE","position":"content"},"interaction":{"id":"rte-1732297859-0","name":"","type":"content"},"mva":{"name":"","tier":"","type":"","category":""}}}} hrefhttps://www.abbvie.com/PatientAccessSupport target_blank>AbbVie.com/PatientAccessSupport/a> to learn more./p>    /div>/div>            div classrich-text>    a idcopayTandC aria-hiddentrue>/a>    div classabbv-rich-text font-10px font-md-13px mt-25 ml-10 abbv-rich-text-common>        p classm-0>sup classml-n10 font-8px font-lg-11px>‡/sup> Terms and Conditions apply. This benefit covers EMRELIS (telisotuzumab vedotin-tllv). Eligibility: Available only to patients with commercial insurance coverage for EMRELIS who meet eligibility criteria. The form of co-pay assistance, enrollment requirements, and processes may vary. Please call 1-844-859-5760 for additional information. Co-pay assistance program is not available to patients receiving reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare including Part D, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If you live or receive treatment in certain states, you may not be eligible. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the EMRELIS Savings Card and patient must call 1-844-859-5760 to stop participation. Co-pay assistance provided under this program may not be transferred to or utilized for the benefit of third parties, including, without limitation, third-party insurance plans and/or pharmacy benefit managers and their agents. By enrolling in the co-pay assistance program, you agree that this program is intended solely for the benefit of you, the patient. Some health plans have established programs referred to as “accumulator adjustment” or “co-pay maximizer” programs. An accumulator adjustment program is one in which payments made by you that are subsidized by manufacturer assistance do not count toward your deductibles and other out-of-pocket cost sharing limitations. Co-pay maximizers are programs in which the amount of your out-of-pocket costs is increased to reflect the availability of support offered by a manufacturer assistance program. Except where prohibited by applicable state law, if your insurance company or health plan implements either an accumulator adjustment or co-pay maximizer program, you will not be eligible for, and agree not to use, co-pay assistance because these programs are inconsistent with our agreed intent that this program is solely for your benefit. You also agree that you are personally responsible for paying any amount of co-pay required after the savings card is applied. Any out-of-pocket costs remaining after the application of the savings card may not be paid by your health plan, pharmacy benefit programs, or any other program. If you learn your insurance company or health plan has implemented either an accumulator adjustment program or a co-pay maximizer program, you agree to inform AbbVie of this fact by calling 1-844-859-5760 to discuss alternative options that may be available to support you. You also agree that you are personally responsible for paying any amount of co-pay required after the savings card is applied. Any out-of-pocket costs remaining after the application of the savings card may not be paid by your health plan, pharmacy benefit programs, or any other program. Subject to all other terms and conditions, the maximum annual benefit that may be available solely for the patient’s benefit under the co-pay assistance program is $25,000 per calendar year. The actual application and use of the benefit available under the co-pay assistance program may vary on a monthly, quarterly, and/or annual basis depending on each individual patient’s plan of insurance and other prescription drug costs. This co-pay assistance program is subject to change, reduction in monetary amount, or discontinuation without any notice. AbbVie in its sole discretion may unilaterally reduce or discontinue the maximum annual benefit for any reason. Except where prohibited by applicable law, this includes potential reduction or discontinuation to ensure that co-pay assistance is utilized solely for the patient’s benefit. Patients may not seek reimbursement for value received from the EMRELIS Savings Card Program from any third-party payers, including insurance plans, flexible spending plans or health savings accounts. Co-pay support made available under this program may not be used with any other coupon, discount, prescription savings card, free trial, or other offer (including any program offered by a third-party insurance plan or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations). Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This assistance offer is not health insurance. The failure to enforce any provision of these Terms and Conditions does not constitute a waiver by AbbVie of that or any other provision. By utilizing this co-pay assistance program, you hereby accept and agree to abide by these terms and conditions. Any individual or entity who enrolls or assists in the enrollment of a patient in the co-pay assistance program represents that the patient meets the eligibility criteria and other requirements described herein. Further, you agree that you currently meet the eligibility criteria and other requirements described herein every time you use the co-pay assistance program. span classfont-weight-bold>To learn about AbbVie’s privacy practices and your privacy choices, visit a hrefhttps://abbv.ie/corpprivacy classabv-custom-txtcolor-white text-underline target_blank data-digitaldata{"digitalData":{"page":{"link":{"name":"","displayTitle":"https://abbv.ie/corpprivacy","type":"external","url":"https://abbv.ie/corpprivacy"},"component":{"type":"content","l10title":"","title":"","name":"RTE","position":"content"},"interaction":{"id":"rte-1184175775-0","name":"","type":"content"},"mva":{"name":"","tier":"","type":"","category":""}}}}>https://abbv.ie/corpprivacy/a>./span>/p>    /div>/div>/div>                					/div>	/div>            div classflexbox parbase>			        		div classabbv-flex-container abv-custom-bgcolor-cream pt-45 pb-45           >							                					div classabbv-flex-item max-width-1200 m-auto p-0 pl-15 pr-15        >                    div classflexbox parbase>			        		div classabbv-flex-container emrelis-homepage-gradient-card emrelis-homepage-gradient-card--cream max-width-md-370 m-auto          >							                					div classabbv-flex-item d-flex flex-column flex-align_items_center flex-justify_center pt-20 pb-30 pb-md-20        >                    div classrich-text>        div classabbv-rich-text font-weight-medium font-14px font-md-17px text-center abbv-rich-text-common>        p classmt-0 mb-10>Sign up forbr classd-block d-md-none />emails about EMRELIS/p>    /div>/div>            div classcta parbase>                                                                        	a data-digitaldata{digitalData:{page:{link:{name:Sign Up,displayTitle:Sign Up,type:internal,url:/content/emrelis/en-us/sign-up},component:{type:content,l10title:,title:Sign up for emails about EMRELIS,name:CTA,position:content},content:{},interaction:{type:,name:Sign Up,id:abbv-cta-705157012,tags:},menu:{}}}} class    abbv-button-primary  emrelis-button-light-green text-center font-18px font-weight-medium max-width-md-274 width-md-274  rolelink aria-labelSign Up href/sign-up target_self data-linktypeinternal aria-hiddenfalse>Sign Up/a>                                                    /div>/div>                					/div>	/div>/div>                					/div>	/div>    /div>        /div>/section>							            div roleregion aria-labelImportant Safety Information classabbv-inline-use-isi>            a idabbv_use_statement aria-hiddentrue>/a>            div classabbv-inline-use abbv-indication-swap>                                                div classrich-text>        div classabbv-rich-text  abbv-rich-text-common>        h3 classtext-blue>USE/h3>p classtext-blue>b>What is EMRELIS?/b>/p>p>EMRELIS™ is a prescription medicine used to treat adults with non-squamous non-small cell lung cancer (NSCLC):/p>ul classmt0>li>that has spread to areas near the lungs (locally advanced) or to other parts of the body (metastatic), b>and/b>/li>li>whose tumors have high c-Met protein overexpression, b>and/b>/li>li>who have received a prior treatment./li>/ul>p>Your healthcare provider will perform a test to make sure EMRELIS is right for you./p>p>It is not known if EMRELIS is safe and effective in children./p>    /div>/div>                            /div>            a idabbv_safety_information aria-hiddentrue>/a>            div classabbv-inline-safety abbv-indication-swap>                                                div classrich-text>        div classabbv-rich-text  abbv-rich-text-common>        h3 classtext-blue mt-40>IMPORTANT SAFETY INFORMATION/h3>h4 classtext-blue>b>What is the most important information I should know about EMRELIS?/b>/h4>p>b>EMRELIS can cause serious side effects, including:/b>/p>ul classmt0>li>b>Nerve problems in your hands or feet (peripheral neuropathy)./b> Nerve problems are common during treatment with EMRELIS and can also be severe. Tell your healthcare provider if you develop any new or worsening signs or symptoms of nerve problems, including:ul classabbv-isi-sublist column-2>li>numbness/li>li>tingling/li>li>burning sensation/li>li>pain or discomfort/li>li>muscle weakness/li>li>difficulty walking/li>/ul>/li>li>b>Lung problems./b> EMRELIS can cause lung problems that may be severe, life-threatening, or that may lead to death. Tell your healthcare provider right away if you develop new or worsening lung symptoms, including:ul classabbv-isi-sublist column-2>li>cough/li>li>trouble breathing or shortness of breath/li>li>fever/li>li>wheezing/li>/ul>/li>li>b>Eye problems./b> Your healthcare provider may send you to an eye care professional to check your eyes if you develop eye problems. Tell your healthcare provider right away if you develop any new or worsening eye problems or vision changes, including:ul classabbv-isi-sublist column-2>li>blurred vision/li>li>dry eyes/li>li>sensitivity to light/li>li>eye pain or swelling/li>li>eye rednessbr /> /li>/ul>/li>li>b>Infusion-related reactions./b> EMRELIS can cause infusion reactions that can be severe or life-threatening. Tell your healthcare provider right away if you develop any signs and symptoms of infusion reactions, including:ul classabbv-isi-sublist column-2>li>itching or rash/li>li>shortness of breath or wheezing/li>li>flushing/li>li>chest discomfort/li>li>fever/li>li>back pain/li>li>chills/li>li>headache/li>li>nausea or vomiting/li>li>feel like passing out/li>/ul>/li>/ul>p>b>Getting medical treatment right away may help keep these problems from becoming more serious./b> Your healthcare provider will check you for these problems during your treatment with EMRELIS and may provide treatment for your side effects. Your healthcare provider may also need to change your dose, temporarily stop, or completely stop treatment with EMRELIS if you have severe side effects./p>p classtext-blue>b>Before receiving EMRELIS, tell your healthcare provider about all of your medical conditions, including if you:/b>/p>ul classmt0>li>have a history of nerve problems/li>li>have lung or breathing problems other than your lung cancer/li>li>have eye problems/li>li>have liver problems/li>li>are pregnant or plan to become pregnant. EMRELIS can harm your unborn baby.ul classabbv-isi-sublist>li>b>Females who are able to become pregnant:/b>ul classabbv-isi-sublist2>li>Your healthcare provider should do a pregnancy test before you start treatment with EMRELIS./li>li>You should use effective birth control (contraception) during treatment and for 2 months after your last dose of EMRELIS./li>li>Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EMRELIS./li>/ul>/li>li>b>Males with female partners who are able to become pregnant:/b>ul classabbv-isi-sublist2>li>You should use an effective birth control during treatment and for 4 months after taking the last dose of EMRELIS./li>/ul>/li>/ul>/li>li>are breastfeeding or plan to breastfeed. It is not known if EMRELIS passes into your breast milk. Do not breastfeed during treatment with EMRELIS and for 1 month after the last dose./li>/ul>p>b>Tell your healthcare provider about all the medicines you take/b>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking certain medicines with EMRELIS may increase your risk of side effects./p>ul>/ul>p classtext-blue>b>How will I receive EMRELIS?/b>/p>ul>li>Your healthcare provider will give you EMRELIS into your vein through an intravenous (IV) line over 30 minutes./li>li>EMRELIS is given 1 time every 2 weeks./li>li>Your healthcare provider will decide how many infusions of EMRELIS you will receive./li>/ul>p classtext-blue>b>What are the possible side effects of EMRELIS?/b>/p>p>b>EMRELIS can cause serious side effects. See “What is the most important information I should know about EMRELIS?”/b>/p>p>b>The most common side effects of EMRELIS include:/b>/p>ul classmt0>li>feeling tired/li>li>decreased appetite/li>li>swelling in the feet, ankles, legs, or hands/li>/ul>p>b>The most common severe abnormal laboratory tests results of EMRELIS include:/b>/p>ul classabbv-isi-sublist column-2>li>decreased white blood cell counts/li>li>increased blood sugar levels/li>li>increased blood liver enzyme levels/li>li>decreased blood phosphorus levels/li>li>decreased blood sodium levels/li>li>decreased red blood cell counts/li>li>decreased blood calcium levelsbr /> /li>/ul>p>EMRELIS may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility./p>p>These are not all the possible side effects of EMRELIS./p>p>Call your doctor for medical advice about side effects./p>p>b>You are encouraged to report negative side effects of prescription drugs to the FDA. Visit a data-digitaldata{"digitalData":{"page":{"link":{"name":"","displayTitle":"www.fda.gov/medwatch","type":"internal","url":"#warnonleavemodalfda"},"component":{"type":"content","l10title":"","title":"","name":"RTE","position":"content"},"interaction":{"id":"rte-540296484-0","name":"","type":"content"},"mva":{"name":"","tier":"","type":"","category":""}}}} href#warnonleavemodalfda targetnew-modal classabbv-modal-open data-idwarnonleavemodalfda>www.fda.gov/medwatch/a> or call a data-digitaldata{"digitalData":{"page":{"link":{"name":"","displayTitle":"new link","type":"internal","url":"tel:1-800-332-1088"},"component":{"type":"content","l10title":"","title":"","name":"RTE","position":"content"},"interaction":{"id":"rte-540296484-1","name":"","type":"content"},"mva":{"name":"","tier":"","type":"","category":""}}}} hreftel:1-800-332-1088 target_blank>1-800-FDA-1088/a>./b>/p>p>b>If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit a data-digitaldata{"digitalData":{"page":{"link":{"name":"AbbVie.com/PatientAccessSupport","displayTitle":"new link","type":"external","url":"https://AbbVie.com/PatientAccessSupport"},"component":{"type":"content","l10title":"","title":"Patient Support","name":"RTE","position":"content"},"interaction":{"id":"rte-540296484-2","name":"","type":"content"},"mva":{"name":"","tier":"","type":"","category":""}}}} hrefhttps://AbbVie.com/PatientAccessSupport target_blank>AbbVie.com/PatientAccessSupport/a> to learn more./b>/p>p>US-TEL-250027/p>    /div>/div>                            /div>            a idabbv_miscisi aria-hiddentrue>/a>            div classabbv-inline-miscisi>                            /div>        /div>                                                    div>                            div classcontainer parbase>    div classabbv-container abv-custom-bgcolor-cream mt-n25 pl-20 pr-20 pb-20>                    div classcontainer parbase>    div classabbv-container please-text>                    div classrich-text>        div classabbv-rich-text reference-txt pl-5x m-0 font-17px font-lg-22px line-height-24px  font-lg-19px line-height-lg-26px abbv-rich-text-common>        p>b>Please see full a hrefhttps://www.rxabbvie.com/pdf/emrelis_pi.pdf target_blank data-digitaldata{"digitalData":{"page":{"link":{"name":"Prescribing information","displayTitle":"Prescribing Information","type":"external","url":"https://www.rxabbvie.com/pdf/emrelis_pi.pdf"},"component":{"type":"content","l10title":"","title":"Prescribing information","name":"RTE","position":"content"},"interaction":{"id":"rte-845920602-0","name":"Prescribing information","type":"content"},"mva":{"name":"","tier":"","type":"","category":""}}}}>Prescribing Information/a>, including a hrefhttps://www.rxabbvie.com/pdf/emrelis_medguide.pdf target_blank data-digitaldata{"digitalData":{"page":{"link":{"name":"Medication Guide","displayTitle":"Medication Guide","type":"external","url":"https://www.rxabbvie.com/pdf/emrelis_medguide.pdf"},"component":{"type":"content","l10title":"","title":"Medication Guide","name":"RTE","position":"content"},"interaction":{"id":"rte-845920602-1","name":"Medication Guide","type":"content"},"mva":{"name":"","tier":"","type":"","category":""}}}}>Medication Guide/a>./b>/p>    /div>/div>    /div>        /div>    /div>        /div>                            div classfooter parbase>    !-- Begin: AbbVie Footer Component -->        footer classabbv-footer abbv-indication-swap abv-custom-txtcolor-white>        div classabbv-footer-content>                                                div>                        ul classabbv-footer-horizontal  >                                                            li>                                                                            										                                                                                    				a data-digitaldata{digitalData:{page:{component:{l10title:,name:footer,position:footer,type:footer,title:footer},link:{displayTitle:Site Map,name:Site Map,type:internal,url:/content/emrelis/en-us/sitemap},interaction:{name:Site Map,location:footer,id:abbv-footer-1981245282-00,type:link,tags:},content:{name:,type:,title:}}}} href/sitemap target_self>Site Map /a>	                                        																				                                                                    /li>                                                            li>                                                                            										                                                                                    				a data-digitaldata{digitalData:{page:{component:{l10title:,name:footer,position:footer,type:footer,title:footer},link:{displayTitle:Accessibility Statement,name:Accessibility Statement,type:external,url:https://www.abbvie.com/accessibility-statement.html},interaction:{name:Accessibility Statement,location:footer,id:abbv-footer-1981245282-01,type:link,tags:},content:{name:,type:,title:}}}} aria-labelAccessibility Statement  - Opens in a new window hrefhttps://www.abbvie.com/accessibility-statement.html target_blank>Accessibility Statement /a>	                                        																				                                                                    /li>                                                            li>                                                                            										                                                                                    				a data-digitaldata{digitalData:{page:{component:{l10title:,name:footer,position:footer,type:footer,title:footer},link:{displayTitle:Contact Us,name:Contact Us,type:external,url:https://www.abbvie.com/contact-us},interaction:{name:Contact Us,location:footer,id:abbv-footer-1981245282-02,type:link,tags:},content:{name:,type:,title:}}}} aria-labelContact Us  - Opens in a new window hrefhttps://www.abbvie.com/contact-us target_blank>Contact Us /a>	                                        																				                                                                    /li>                                                            li>                                                                            										                                                                                    				a data-digitaldata{digitalData:{page:{component:{l10title:,name:footer,position:footer,type:footer,title:footer},link:{displayTitle:Terms of Use,name:Terms of Use,type:external,url:https://www.abbvie.com/terms-of-use},interaction:{name:Terms of Use,location:footer,id:abbv-footer-1981245282-03,type:link,tags:},content:{name:,type:,title:}}}} aria-labelTerms of Use  - Opens in a new window hrefhttps://www.abbvie.com/terms-of-use target_blank>Terms of Use /a>	                                        																				                                                                    /li>                                                            li>                                                                            										                                                                                    				a data-digitaldata{digitalData:{page:{component:{l10title:,name:footer,position:footer,type:footer,title:footer},link:{displayTitle:Privacy Notice,name:Privacy Notice,type:external,url:https://privacy.abbvie/privacy-policies/us-privacy-policy.html},interaction:{name:Privacy Notice,location:footer,id:abbv-footer-1981245282-04,type:link,tags:},content:{name:,type:,title:}}}} aria-labelPrivacy Notice  - Opens in a new window hrefhttps://privacy.abbvie/privacy-policies/us-privacy-policy.html target_blank>Privacy Notice /a>	                                        																				                                                                    /li>                                                            li>                                                                            										                                                                                    				a data-digitaldata{digitalData:{page:{component:{l10title:,name:footer,position:footer,type:footer,title:footer},link:{displayTitle:Consumer Health Data Privacy Notice,name:Consumer Health Data Privacy Notice,type:external,url:https://abbv.ie/PrivacyConsumerHealth},interaction:{name:Consumer Health Data Privacy Notice,location:footer,id:abbv-footer-1981245282-05,type:link,tags:},content:{name:,type:,title:}}}} aria-labelConsumer Health Data Privacy Notice - Opens in a new window hrefhttps://abbv.ie/PrivacyConsumerHealth target_blank>Consumer Health Data Privacy Notice/a>	                                        																				                                                                    /li>                                                            li>                                                                            										                                                                                    			a data-digitaldata{digitalData:{page:{component:{l10title:,name:footer,position:footer,type:footer,title:footer},link:{displayTitle:Cookies Settings,name:Cookies Settings,type:internal,url:#},interaction:{name:Cookies Settings,location:footer,id:abbv-footer-1981245282-06,type:link,tags:},content:{name:,type:,title:}}}} hrefjavascript:void(0) idot-sdk-btn1 classot-sdk-show-settings titleCookies Settings>Cookies Settings/a>		                                        																				                                                                    /li>                                                            li>                                                                            										                                                                                    				a data-digitaldata{digitalData:{page:{component:{l10title:,name:footer,position:footer,type:footer,title:footer},link:{displayTitle:Your Privacy Choices,name:Your Privacy Choices,type:external,url:https://abbviemetadata.my.site.com/AbbvieDSRM/s/?languageen_US},interaction:{name:Your Privacy Choices,location:footer,id:abbv-footer-1981245282-07,type:link,tags:},content:{name:,type:,title:}}}} aria-labelYour Privacy Choices - Opens in a new window hrefhttps://abbviemetadata.my.site.com/AbbvieDSRM/s/?languageen_US target_blank>Your Privacy Choices/a>	                                        																				                                                                    /li>                                                    /ul>                        /ul>                    /div>                                                    div classabbv-legal-text abbv-rich-text-common>p>u>a data-digitaldata{"digitalData":{"page":{"link":{"name":"","displayTitle":"Legal Notices/Privacy Notice","type":"external","url":"https://privacy.abbvie/privacy-policies/us-privacy-policy.html"},"component":{"type":"content","l10title":"","title":"footer","name":"RTE","position":"content"},"interaction":{"id":"rte-1981245282-0","name":"","type":"content"},"mva":{"name":"","tier":"","type":"","category":""}}}} hrefhttps://privacy.abbvie/privacy-policies/us-privacy-policy.html target_blank>Legal Notices/Privacy Notice/a>/u>. © 2025 AbbVie. All rights reserved. EMRELISsup>TM/sup> and its design are trademarks of AbbVie Inc.br classd-inline d-md-none>span classmt-30 mb-30 d-block m-md-0 d-md-inline>US-TEL-240039 v2/span>/p>p>If you have any questions about AbbVie’s EMRELIS.com website that have not been answered, a data-digitaldata{"digitalData":{"page":{"link":{"name":"","displayTitle":"click here","type":"external","url":"https://www.abbvie.com/contactus.html"},"component":{"type":"content","l10title":"","title":"footer","name":"RTE","position":"content"},"interaction":{"id":"rte-1981245282-1","name":"","type":"content"},"mva":{"name":"","tier":"","type":"","category":""}}}} hrefhttps://www.abbvie.com/contactus.html target_blank>u>click here/u>/a>. This website and the information contained herein is intended for use by US residents only and is provided for informational purposes only./p>/div>            p classabbv-legal-number>US-TEL-240039 v1/p>            div classlogo styletext-align:right;>                                                                            a data-digitaldata{digitalData:{page:{component:{name:footer,position:footer,type:footer,title:footer},link:{displayTitle:AbbVie Logo,name:AbbVie Logo,type:external,url:https://www.abbvie.com},interaction:{name:AbbVie Logo,location:footer,id:abbv-footer-1981245282,type:link,tags:},content:{name:,type:,title:}}}} hrefhttps://www.abbvie.com target_blank>                                                                             svg version1.1 idfooter-logo-id roleimg aria-labelAbbVie Logo, Opens in a new window xmlnshttp://www.w3.org/2000/svg xmlns:xlinkhttp://www.w3.org/1999/xlink x0px y0px viewBox0 0 124.4 21.5 styleenable-background:new 0 0 124.4 21.5; xml:spacepreserve>                                 g>                                     path dM123.8,20.8c0-1.3-0.8-1.8-2-1.8c-0.7,0-9.2,0-9.2,0c-4.5,0-5.6-2.7-5.8-4.4c0,0,9.5,0,12.5,0c3.8,0,5-2.8,5-4.6 c0-1.9-1.2-4.6-5-4.6c-3.4,0-6.9,0-6.9,0c-6.5,0-8.6,4.4-8.6,8c0,3.9,2.4,8,8.6,8h11.4C123.8,21.5,123.8,20.9,123.8,20.8z M112.6,7.8c1,0,4.6,0,6,0c2.2,0,2.7,1.3,2.7,2.2c0,0.8-0.5,2.2-2.7,2.2c-1.5,0-12,0-12,0C106.8,10.8,108.1,7.8,112.6,7.8z M85.9,20.5c-0.7,0.9-1,1.3-1.7,1.3c-0.9,0-1.1-0.4-1.7-1.3c-1.4-2-9.8-15-9.8-15s0.6,0,1.2,0c2,0,2.6,0.9,3.2,1.9 c0.5,0.8,7.3,11.2,7.3,11.2s6.4-9.9,7.3-11.3c0.6-0.9,1.4-1.8,3.3-1.8c0.4,0,0.9,0,0.9,0S87.1,18.9,85.9,20.5z M22.8,21.5 c-1.5,0-2.1-0.6-2.3-1.8L20.1,18c-0.4,0.7-2.4,3.5-6.8,3.5c0,0-2.2,0-4.5,0c-6.8,0-8.7-4.6-8.7-8c0-3.8,2.3-8,8.7-8 c1.3,0,2.7,0,4.8,0c4.9,0,7.6,2.8,8.2,6.3c0.5,2.9,1.8,9.7,1.8,9.7S23.3,21.5,22.8,21.5z M12.9,8c-1.6,0-2,0-3.8,0 C4.5,8,3,10.9,3,13.5S4.5,19,9.1,19c1.9,0,2.5,0,3.8,0c4.8,0,6.1-3,6.1-5.5C19,11.3,17.8,8,12.9,8z M99,2.9c0.7,0,1.4-0.4,1.4-1.3 c0-0.2,0-0.4,0-0.5c0-0.8-0.7-1.3-1.4-1.3c-0.7,0-1.4,0.4-1.4,1.3c0,0.1,0,0.3,0,0.5C97.6,2.5,98.3,2.9,99,2.9z M97.7,5.5 c0,0,0.4,0,0.6,0c1.3,0,2.1,0.7,2.1,2.1c0,0.2,0,13.9,0,13.9s-0.3,0-0.6,0c-1.3,0-2.1-0.8-2.1-2.2C97.7,19.2,97.7,5.5,97.7,5.5z M28.1,7.8c0.6-0.6,2.4-2.3,5.9-2.3c0,0,2.2,0,4.5,0c6.8,0,8.8,4.6,8.8,8c0,3.8-2.4,8-8.8,8c-1.3,0-2.7,0-4.8,0 c-4.9,0-8.4-3.1-8.4-8c0-1.6,0-13.4,0-13.4s0.5,0,0.8,0c1.4,0,2,0.7,2,1.9C28.1,2.2,28.1,7.8,28.1,7.8z M34.4,19c1.6,0,2,0,3.8,0 c4.5,0,6.1-2.9,6.1-5.5S42.8,8,38.2,8c-1.9,0-2.5,0-3.8,0c-4.8,0-6.1,3-6.1,5.5C28.2,15.7,29.5,19,34.4,19z M53.2,7.8 c0.6-0.6,2.4-2.3,5.9-2.3c0,0,2.2,0,4.5,0c6.8,0,8.7,4.6,8.7,8c0,3.8-2.3,8-8.7,8c-1.3,0-2.7,0-4.8,0c-4.9,0-8.4-3.1-8.4-8 c0-1.6,0-13.4,0-13.4s0.5,0,0.8,0c1.4,0,2,0.7,2,1.9C53.2,2.2,53.2,7.8,53.2,7.8z M59.5,19c1.6,0,2,0,3.8,0c4.6,0,6.1-2.9,6.1-5.5 S67.9,8,63.3,8c-1.9,0-2.4,0-3.8,0c-4.8,0-6.1,3-6.1,5.5C53.3,15.7,54.6,19,59.5,19z/>                                 /g>                             /svg>                                            /a>                            /div>            div classabbv-clear>/div>        /div>    /footer>    !-- End: AbbVie Footer Component -->/div>    /div>    						div classabbv-dimmer>/div>			!-- Section for Back To Top Component Start-->											button classabbv-back-to-top abbv-button-plain abbv-icon-arrow_upward i-a aria-labelback to top data-digitaldata{digitalData:{page:{component:{l10title:,name:Back to top,position:Footer,type:Navigation,title:},link:{displayTitle:Top,name:Back to top,type:internal,url:},interaction:{name:,id:abbv-backtotop-1118555709,type:link,tags:},mva:{tier:,name:,type:,category:},menu:{},content:{}}}}>/button>						!-- Section for Back to Top Component End-->		/div>		div>/div>		div>                            div classmodal parbase>	!-- Begin: AbbVie Modal Component -->										div classabbv-modal warnonleavemodalfda width-90-percent abv-custom-bgcolor-cream max-width-800 js-must-interact   data-idwarnonleavemodalfda data-cookie-expire0 aria-modaltrue roledialog tabindex-1 aria-hiddenfalse aria-labelLeaving AbbVie Website>				  	div classabbv-modal-content-container>						span classabbv-modal-close abbv-icon-close i-a rolebutton aria-labelclose tabindex0 data-digitaldata{digitalData:{page:{component:{l10title:,name:modal,position:Content,type:Navigation,title:},link:{displayTitle:modal,name:Close,type:internal,url:},interaction:{name:,id:abbv-modal-1953247932,type:link,tags:},mva:{tier:,name:,type:,category:},menu:{},content:{}}}}>						/span>						div classabbv-modal-content>							div classabbv-animation-loading>/div>															            div classflexbox parbase>			        		div classabbv-flex-container wol-modal-buttons-container p-md-30 p-10 pt-30 pb-30          >							                					div classabbv-flex-item m-0 p-0        >                    div classtitles parbase>div classabbv-title >    h2 classfont-22px font-lg-22px font-weight-bold >Leaving AbbVie Website/h2>/div>/div>            div classrich-text>        div classabbv-rich-text font-weight-semiregular line-height-22px line-height-md-26px mb-35 abbv-rich-text-common>        p classmt-20 mb-25>You are leaving the EMRELIS site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility./p>p classmt-60 mt-md-35 mb-md-35 mb-75>Conversely, the presence of this link does not imply the linked site’s endorsement of EMRELIS.com or AbbVie./p>p>Do you wish to leave this site?/p>    /div>/div>            div classflexbox parbase>			        		div classabbv-flex-container flex-row m-auto modal-buttons-container flex-align_items_center flex-lg-justify_start          >							                					div classabbv-flex-item m-0 p-0  width-140 max-width-140        >                    div classcta parbase>                                                                        	a data-digitaldata{digitalData:{page:{link:{name:Yes,displayTitle:Yes,type:external,url:https://www.fda.gov/medwatch},component:{type:content,l10title:,title:You are leaving the product website,name:CTA,position:content},content:{},interaction:{type:,name:Yes,id:abbv-cta-946650886,tags:},menu:{}}}} class    abbv-button-primary  abbv-modal-close-inline width-135 border-rad-3 text-center pt-15 pb-15 font-13px  rolelink aria-labelYes, Opens in a new window hrefhttps://www.fda.gov/medwatch target_blank data-linktypeexternal aria-hiddenfalse>Yes/a>                                                    /div>/div>                							                					div classabbv-flex-item m-0 p-0 width-140 max-width-140 ml-10        >                    div classcta parbase>                                                                        	a data-digitaldata{digitalData:{page:{link:{name:No,displayTitle:No,type:internal,url:},component:{type:content,l10title:,title:You are leaving the product website,name:CTA,position:content},content:{},interaction:{type:,name:No,id:abbv-cta-1311183367,tags:},menu:{}}}} class    abbv-button-primary  abbv-modal-close-inline width-135 border-rad-3 text-center pt-15 pb-15 font-13px  rolelink aria-labelNo tabindex0 target_self data-linktypeinternal aria-hiddenfalse>No/a>                                                    /div>/div>                					/div>	/div>/div>                					/div>	/div>																				/div>					/div>				/div>																														!-- End: AbbVie Modal Component -->/div>                            div classnewpar new section>/div>                            div classpar iparys_inherited>                /div>    /div>		                            div classsafety-bar parbase>			!-- Begin: AbbVie Safety Bar Component -->				div classabbv-safety-bar abbv-indication-swap abbv-isi-content >			div classabbv-safety-bar-button-plus abbv-icon-add_circle i-a rolebutton aria-labelExpand Safety Information data-digitaldata{digitalData:{page:{component:{l10title:,name:Safety Bar,position:Footer,type:Content,title:},link:{displayTitle:Safety Bar,name:Expand,type:internal,url:},interaction:{name:Expand,id:abbv-safetybar-544202375,type:link,tags:},mva:{tier:,name:,type:,category:},menu:{},content:{}}}}>/div>			div classabbv-safety-bar-button-minus abbv-icon-remove_circle i-a aria-labelMinimize Safety Information data-digitaldata{digitalData:{page:{component:{l10title:,name:Safety Bar,position:Footer,type:Content,title:},link:{displayTitle:Safety Bar,name:Collapse,type:internal,url:},interaction:{name:Collapse,id:abbv-safetybar-544202375,type:link,tags:},mva:{tier:,name:,type:,category:},menu:{},content:{}}}}>/div>			div classabbv-safety-bar-fade>/div>			div classabbv-safety-bar-content abbv-safety-bar-less abbv-safety-bar-content-minimized-desktop>				div classabbv-row-container>					div classabbv-row abbv-row-flush>						div classabbv-col abbv-col-6>							h3 classtext-blue mt-5>IMPORTANT SAFETY INFORMATION/h3>h4 classtext-blue font-weight-bold font-18px>What is the most important information I should know about EMRELIS?/h4>p classfont-weight-bold>EMRELIS can cause serious side effects, including:/p>ul classmt0>li>span classfont-weight-bold>Nerve problems in your hands or feet (peripheral neuropathy)/span>. Nerve problems are common during treatment with EMRELIS and can also be severe. Tell your healthcare provider if you/li>/ul>						/div>						div classabbv-col abbv-col-6>							h3 classtext-blue mt-5>USE/h3>p classtext-blue font-weight-bold>What is EMRELIS?/p>p>EMRELIS™ is a prescription medicine used to treat adults with non-squamous non-small cell lung cancer (NSCLC):/p>ul classmt0>li>that has spread to areas near the lungs (locally advanced) or to other parts of the body (metastatic), span classfont-weight-bold>and/span>/li>li>whose tumors have high c-Met protein overexpression, span classfont-weight-bold>and/span>/li>/ul>						/div>					/div>				/div>			/div>			div classabbv-safety-bar-content abbv-safety-bar-less abbv-safety-bar-content-minimized-mobile>				div classabbv-row-container>					div classabbv-row abbv-row-flush>						div classabbv-col abbv-col-6>							h3 classtext-blue mt-5>IMPORTANT SAFETY INFORMATION/h3>h4 classtext-blue font-weight-bold font-18px>What is the most important information I should know about EMRELIS?/h4>p classfont-weight-bold>EMRELIS can cause serious side effects, including:/p>ul classmt0>li>b>Nerve problems in your hands or feet (peripheral neuropathy)./b> Nerve problems are common during treatment with EMRELIS and can also be severe. Tell your healthcare provider if you/li>/ul>						/div>						div classabbv-col abbv-col-6>							h3 classtext-blue mt-5>USE/h3>p classtext-blue font-weight-bold>What is EMRELIS?/p>p>EMRELIS™ is a prescription medicine used to treat adults with non-squamous non-small cell lung cancer (NSCLC):/p>ul classmt0>li>that has spread to areas near the lungs (locally advanced) or to other parts of the body (metastatic), span classfont-weight-bold>and/span>/li>li>whose tumors have high c-Met protein overexpression, span classfont-weight-bold>and/span>/li>/ul>						/div>					/div>				/div>			/div>			div classabbv-safety-bar-content abbv-safety-bar-more abbv-safety-bar-content-minimized-desktop-more>				div classabbv-row-container>					div classabbv-row abbv-row-flush>						div classabbv-col abbv-col-6>							h3 classtext-blue mt-5>IMPORTANT SAFETY INFORMATION/h3>h4 classtext-blue font-weight-bold font-18px>What is the most important information I should know about EMRELIS?/h4>p classfont-weight-bold>EMRELIS can cause serious side effects, including:/p>ul classmt0>li>span classfont-weight-bold>Nerve problems in your hands or feet (peripheral neuropathy)/span>. Nerve problems are common during treatment with EMRELIS and can also be severe. Tell your healthcare provider if you/li>/ul>						/div>						div classabbv-col abbv-col-6>							h3 classtext-blue mt-5>USE/h3>p classtext-blue font-weight-bold>What is EMRELIS?/p>p>EMRELIS™ is a prescription medicine used to treat adults with non-squamous non-small cell lung cancer (NSCLC):/p>ul classmt0>li>that has spread to areas near the lungs (locally advanced) or to other parts of the body (metastatic), span classfont-weight-bold>and/span>/li>li>whose tumors have high c-Met protein overexpression, span classfont-weight-bold>and/span>/li>/ul>						/div>					/div>				/div>			/div>			div classabbv-safety-bar-content abbv-safety-bar-more abbv-safety-bar-content-minimized-mobile-more>				div classabbv-row-container>					div classabbv-row abbv-row-flush>						div classabbv-col abbv-col-6>							h3 classtext-blue mt-5>IMPORTANT SAFETY INFORMATION/h3>h4 classtext-blue font-weight-bold font-18px>What is the most important information I should know about EMRELIS?/h4>p classfont-weight-bold>EMRELIS can cause serious side effects, including:/p>ul classmt0>li>b>Nerve problems in your hands or feet (peripheral neuropathy)./b> Nerve problems are common during treatment with EMRELIS and can also be severe. Tell your healthcare provider if you/li>/ul>						/div>						div classabbv-col abbv-col-6>							h3 classtext-blue mt-5>USE/h3>p classtext-blue font-weight-bold>What is EMRELIS?/p>p>EMRELIS™ is a prescription medicine used to treat adults with non-squamous non-small cell lung cancer (NSCLC):/p>ul classmt0>li>that has spread to areas near the lungs (locally advanced) or to other parts of the body (metastatic), span classfont-weight-bold>and/span>/li>li>whose tumors have high c-Met protein overexpression, span classfont-weight-bold>and/span>/li>/ul>						/div>					/div>				/div>			/div>			div classabbv-safety-bar-content abbv-safety-bar-content-maximized>				div classabbv-row-container>					div classabbv-row abbv-row-flush>						div classabbv-col abbv-col-12>							            div classrich-text>        div classabbv-rich-text  abbv-rich-text-common>        h3 classtext-blue>USE/h3>p classtext-blue>b>What is EMRELIS?/b>/p>p>EMRELIS™ is a prescription medicine used to treat adults with non-squamous non-small cell lung cancer (NSCLC):/p>ul classmt0>li>that has spread to areas near the lungs (locally advanced) or to other parts of the body (metastatic), b>and/b>/li>li>whose tumors have high c-Met protein overexpression, b>and/b>/li>li>who have received a prior treatment./li>/ul>p>Your healthcare provider will perform a test to make sure EMRELIS is right for you./p>p>It is not known if EMRELIS is safe and effective in children./p>    /div>/div>						/div>						div classabbv-col abbv-col-12>							            div classrich-text>        div classabbv-rich-text  abbv-rich-text-common>        h3 classtext-blue mt-40>IMPORTANT SAFETY INFORMATION/h3>h4 classtext-blue>b>What is the most important information I should know about EMRELIS?/b>/h4>p>b>EMRELIS can cause serious side effects, including:/b>/p>ul classmt0>li>b>Nerve problems in your hands or feet (peripheral neuropathy)./b> Nerve problems are common during treatment with EMRELIS and can also be severe. Tell your healthcare provider if you develop any new or worsening signs or symptoms of nerve problems, including:ul classabbv-isi-sublist column-2>li>numbness/li>li>tingling/li>li>burning sensation/li>li>pain or discomfort/li>li>muscle weakness/li>li>difficulty walking/li>/ul>/li>li>b>Lung problems./b> EMRELIS can cause lung problems that may be severe, life-threatening, or that may lead to death. Tell your healthcare provider right away if you develop new or worsening lung symptoms, including:ul classabbv-isi-sublist column-2>li>cough/li>li>trouble breathing or shortness of breath/li>li>fever/li>li>wheezing/li>/ul>/li>li>b>Eye problems./b> Your healthcare provider may send you to an eye care professional to check your eyes if you develop eye problems. Tell your healthcare provider right away if you develop any new or worsening eye problems or vision changes, including:ul classabbv-isi-sublist column-2>li>blurred vision/li>li>dry eyes/li>li>sensitivity to light/li>li>eye pain or swelling/li>li>eye rednessbr /> /li>/ul>/li>li>b>Infusion-related reactions./b> EMRELIS can cause infusion reactions that can be severe or life-threatening. Tell your healthcare provider right away if you develop any signs and symptoms of infusion reactions, including:ul classabbv-isi-sublist column-2>li>itching or rash/li>li>shortness of breath or wheezing/li>li>flushing/li>li>chest discomfort/li>li>fever/li>li>back pain/li>li>chills/li>li>headache/li>li>nausea or vomiting/li>li>feel like passing out/li>/ul>/li>/ul>p>b>Getting medical treatment right away may help keep these problems from becoming more serious./b> Your healthcare provider will check you for these problems during your treatment with EMRELIS and may provide treatment for your side effects. Your healthcare provider may also need to change your dose, temporarily stop, or completely stop treatment with EMRELIS if you have severe side effects./p>p classtext-blue>b>Before receiving EMRELIS, tell your healthcare provider about all of your medical conditions, including if you:/b>/p>ul classmt0>li>have a history of nerve problems/li>li>have lung or breathing problems other than your lung cancer/li>li>have eye problems/li>li>have liver problems/li>li>are pregnant or plan to become pregnant. EMRELIS can harm your unborn baby.ul classabbv-isi-sublist>li>b>Females who are able to become pregnant:/b>ul classabbv-isi-sublist2>li>Your healthcare provider should do a pregnancy test before you start treatment with EMRELIS./li>li>You should use effective birth control (contraception) during treatment and for 2 months after your last dose of EMRELIS./li>li>Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EMRELIS./li>/ul>/li>li>b>Males with female partners who are able to become pregnant:/b>ul classabbv-isi-sublist2>li>You should use an effective birth control during treatment and for 4 months after taking the last dose of EMRELIS./li>/ul>/li>/ul>/li>li>are breastfeeding or plan to breastfeed. It is not known if EMRELIS passes into your breast milk. Do not breastfeed during treatment with EMRELIS and for 1 month after the last dose./li>/ul>p>b>Tell your healthcare provider about all the medicines you take/b>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking certain medicines with EMRELIS may increase your risk of side effects./p>ul>/ul>p classtext-blue>b>How will I receive EMRELIS?/b>/p>ul>li>Your healthcare provider will give you EMRELIS into your vein through an intravenous (IV) line over 30 minutes./li>li>EMRELIS is given 1 time every 2 weeks./li>li>Your healthcare provider will decide how many infusions of EMRELIS you will receive./li>/ul>p classtext-blue>b>What are the possible side effects of EMRELIS?/b>/p>p>b>EMRELIS can cause serious side effects. See “What is the most important information I should know about EMRELIS?”/b>/p>p>b>The most common side effects of EMRELIS include:/b>/p>ul classmt0>li>feeling tired/li>li>decreased appetite/li>li>swelling in the feet, ankles, legs, or hands/li>/ul>p>b>The most common severe abnormal laboratory tests results of EMRELIS include:/b>/p>ul classabbv-isi-sublist column-2>li>decreased white blood cell counts/li>li>increased blood sugar levels/li>li>increased blood liver enzyme levels/li>li>decreased blood phosphorus levels/li>li>decreased blood sodium levels/li>li>decreased red blood cell counts/li>li>decreased blood calcium levelsbr /> /li>/ul>p>EMRELIS may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility./p>p>These are not all the possible side effects of EMRELIS./p>p>Call your doctor for medical advice about side effects./p>p>b>You are encouraged to report negative side effects of prescription drugs to the FDA. Visit a data-digitaldata{"digitalData":{"page":{"link":{"name":"","displayTitle":"www.fda.gov/medwatch","type":"internal","url":"#warnonleavemodalfda"},"component":{"type":"content","l10title":"","title":"","name":"RTE","position":"content"},"interaction":{"id":"rte-540296484-0","name":"","type":"content"},"mva":{"name":"","tier":"","type":"","category":""}}}} href#warnonleavemodalfda targetnew-modal classabbv-modal-open data-idwarnonleavemodalfda>www.fda.gov/medwatch/a> or call a data-digitaldata{"digitalData":{"page":{"link":{"name":"","displayTitle":"new link","type":"internal","url":"tel:1-800-332-1088"},"component":{"type":"content","l10title":"","title":"","name":"RTE","position":"content"},"interaction":{"id":"rte-540296484-1","name":"","type":"content"},"mva":{"name":"","tier":"","type":"","category":""}}}} hreftel:1-800-332-1088 target_blank>1-800-FDA-1088/a>./b>/p>p>b>If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit a data-digitaldata{"digitalData":{"page":{"link":{"name":"AbbVie.com/PatientAccessSupport","displayTitle":"new link","type":"external","url":"https://AbbVie.com/PatientAccessSupport"},"component":{"type":"content","l10title":"","title":"Patient Support","name":"RTE","position":"content"},"interaction":{"id":"rte-540296484-2","name":"","type":"content"},"mva":{"name":"","tier":"","type":"","category":""}}}} hrefhttps://AbbVie.com/PatientAccessSupport target_blank>AbbVie.com/PatientAccessSupport/a> to learn more./b>/p>p>US-TEL-250027/p>    /div>/div>						/div>														 			/div>				/div>			/div> 		/div>	!-- End: AbbVie Safety Bar Component -->	/div>                            div classnewpar new section>/div>                            div classpar iparys_inherited>                /div>    		svg classabbv-svg-defs version1.1 xmlnshttp://www.w3.org/2000/svg xmlns:xlinkhttp://www.w3.org/1999/xlink xml:spacepreserve>		defs>		  linearGradient idabbv-h-gradient-1 x10 y10 x21 y20>			stop offset0% stop-color#23417b/>			stop offset100% stop-color#071d49/>		  /linearGradient>		  linearGradient idabbv-h-gradient-2 x10 y10 x21 y20>			stop offset0% stop-color#c0bdc2/>			stop offset100% stop-color#96999e/>		  /linearGradient>		  linearGradient idabbv-v-gradient-1 x10 y10 x20 y21>			stop offset0% stop-color#23417b/>			stop offset100% stop-color#071d49/>		  /linearGradient>		  linearGradient idabbv-v-gradient-2 x10 y10 x20 y21>			stop offset0% stop-color#c0bdc2/>			stop offset100% stop-color#96999e/>		  /linearGradient>		  radialGradient idabbv-r-gradient-1>			stop offset0% stop-color#23417b/>			stop offset100% stop-color#071d49/>		  /radialGradient>		  radialGradient idabbv-r-gradient-2>			stop offset0% stop-color#c0bdc2/>			stop offset100% stop-color#96999e/>		  /radialGradient>		   clipPath idabbv-square-point clipPathUnitsobjectBoundingBox>			rect x.15 y.15 width.7 height.7/>		  /clipPath>		  clipPath idabbv-diamond-point clipPathUnitsobjectBoundingBox>			path dM0,.5 L.5,0 L1,.5 L.5,1 z/>		  /clipPath>		  		/defs>	/svg>	/div>										    script src/etc/clientlibs/common-elements/clientlibs/v1/components.min.5f38a1b241fdca630c289f030c0d8797.js>/script>						/body>            /html>

View on OTX | View on ThreatMiner

Data with thanks to AlienVault OTX, VirusTotal, Malwr and others. [Sitemap]

Domain > www.emrelis.com

Is this malicious?

DNS Resolutions

Port 80

Port 443